10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2013

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 000-53298

MYOS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	90-0772394
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

45 Horsehill Road, Suite 106 Cedar Knolls, NJ.	07927
(Address of Principal Executive Offices)	(Zip Code)

(973) 509-0444

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x     No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x     No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

o  Large accelerated filer	o  Accelerated filer
o  Non-accelerated filer	x  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes  o     No  x

As of November 8, 2013, the registrant had 111,372,282 shares of common stock outstanding.

INDEX	Page
PART 1-FINANCIAL INFORMATION	2
Item 1.    Financial Statements	2
Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012	2
Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2013 and 2012 and the period from inception (April 11, 2007) to September 30, 2013	3
Consolidated Statements of Changes in Stockholders’ Equity (unaudited) for the period from inception (April 11, 2007) to September 30, 2013	4
Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2013 and 2012 and for the period from inception (April 11, 2007) to September 30, 2013	5 to 6
Notes to Consolidated Financial Statements	7to 21
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.    Quantitative and Qualitative Disclosures about Market Risk	25
Item 4.    Control and Procedures	25
PART II-OTHER INFORMATION
Item 1.    Legal Proceedings	25
Item 1A.  Risk Factors	25
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.    Defaults Upon Senior Securities	26
Item 4.    Mine Safety Disclosures	26
Item 5.    Other Information	26
Item 6.    Exhibits	26
SIGNATURES	27

PART 1-FINANCIAL INFORMATION

Item 1. Financial Statements

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2013			2012
	(Unaudited)
ASSETS
Current assets
Cash	$	1,883,464		$	3,979,662
Accounts receivable		214,740			201,579
Inventories		10,869			218,317
Prepaid expenses and other current assets		233,840			84,388
Total current assets		2,342,913			4,483,946
Fixed assets, net of accumulated depreciation		327,959			8,389
Intellectual property		2,000,000			2,000,000
Intangible assets		38,117			36,440
Total assets	$	4,708,989		$	6,528,775
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses	$	213,556		$	208,898
Total current liabilities		213,556			208,898
Derivatives liability		43,950			121,900
Total liabilities		257,506			330,798
Stockholders' equity
Preferred stock, $.001 par value; 25,000,000 shares authorized;
no shares issued and outstanding		-			-
Common stock, $.001 par value, 300,000,000 shares authorized;
111,372,282 shares issued and outstanding at September 30, 2013
110,033,282 shares issued and outstanding at December 31, 2012		111,372			110,033
Additional paid-in capital		16,840,133			15,733,650
Deficit accumulated during development stage		(12,500,022	)		(9,645,706	)
Total stockholders' equity		4,451,483			6,197,977
Total liabilities and stockholders' equity	$	4,708,989		$	6,528,775
The accompanying notes are an integral part of the financial statements

2

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

													April 11, 2007
													(Inception Date)
	Three Months Ended September 30,						Nine Months Ended September 30,						to September 30,
	2013			2012			2013			2012			2013
Revenue	$	917,574		$	365,934		$	1,910,287		$	734,363		$	2,921,489
Cost of sales		427,431			354,590			872,188			655,997			1,785,154
Gross profit		490,143			11,344			1,038,099			78,366			1,136,335
General and administrative expenses		1,271,562			1,058,968			3,896,374			2,091,975			11,772,539
Loss from operations		(781,419	)		(1,047,624	)		(2,858,275	)		(2,013,609	)		(10,636,204	)
OTHER INCOME (EXPENSE)
Interest income		847			5,561			3,969			5,561			12,445
Interest expense		(10	)		(106	)		(10	)		(802,614	)		(827,030	)
Value of warrants in excess of the amount of additional paid-in capital received in the related private placement of restricted common stock		-			-			-			-			(2,405,303	)
Change in fair value of warrants		-			229,591			-			(16,173	)		4,085,570
Impairment charge - intellectual property		-			-			-			-			(2,662,000	)
Amortization of deferred financing costs		-			-			-			(69,451	)		(80,000	)
Gain on forgiveness of debt		-			-			-			-			12,500
Total other income (expense)		837			235,046			3,959			(882,677	)		(1,863,818	)
Net loss	$	(780,582	)	$	(812,578	)	$	(2,854,316	)	$	(2,896,286	)	$	(12,500,022	)
Weighted average number of common shares outstanding, basic and diluted		110,907,236			106,387,551			110,597,267			86,017,222
Basic and diluted net loss per share attributable to common stockholders	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

The accompanying notes are an integral part of the financial statements

3

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

For the period from April 11, 2007 (date of inception) to September 30, 2013

(Unaudited)

	Common Stock							Deficit accumulated during development stage
	Shares		Amount $.001 par		Additional paid-in capital						Total stockholders' equity (deficit)
Balance at April 11, 2007		-	$	-	$	-		$	-		$	-
Common stock issued for cash at $0.0002 per share		28,000,000		28,000		(23,000	)					5,000
Common stock issued for cash at $0.004 per share		21,000,000		21,000		54,000						75,000
Net loss									(60,185	)		(60,185	)
Balance at December 31, 2007		49,000,000		49,000		31,000			(60,185	)		19,815
Net loss									(17,928	)		(17,928	)
Balance at December 31, 2008		49,000,000		49,000		31,000			(78,113	)		1,887
Net loss									(39,308	)		(39,308	)
Balance at December 31, 2009		49,000,000		49,000		31,000			(117,421	)		(37,421	)
Net loss									(16,525	)		(16,525	)
Balance at December 31, 2010		49,000,000		49,000		31,000			(133,946	)		(53,946	)
Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property		7,024,000		7,024		3,504,976						3,512,000
Fair value of shares transferred from existing stockholder to the CEO in connection with employment agreement						1,500,000						1,500,000
Proceeds from private placements of restricted common stock		8,334,997		8,335		2,472,165						2,480,500
Offering costs						(45,000	)					(45,000	)
Fair value of warrants issued to private placement investors						(2,432,365	)					(2,432,365	)
Shares issued for services		2,055,000		2,055		688,138						690,193
Vesting of options and shares issued to directors and advisory board members						360,402						360,402
Shares issued in connection with debt		400,000		400		59,600						60,000
Net loss									(5,597,300	)		(5,597,300	)
Balance at December 31, 2011		66,813,997		66,814		6,138,916			(5,731,246	)		474,484
Proceeds from private placements of restricted common stock		34,430,000		34,430		6,855,560						6,889,990
Offering costs						(178,800	)					(178,800	)
Shares issued to COO		750,000		750		(750	)					-
Shares issued to employee		10,000		10		2,690						2,700
Shares issued for services		3,423,395		3,423		451,154						454,577
Shares issued in debt conversions		2,885,550		2,885		1,343,254						1,346,139
Shares issued in exchange for warrants		1,603,673		1,604		750,579						752,183
Shares issued for exercise of warrants		116,667		117		11,550						11,667
Vesting of options and shares issued to officers, directors, advisory board members, consultants and employees						359,497						359,497
Net loss									(3,914,460	)		(3,914,460	)
Balance at December 31, 2012		110,033,282	$	110,033	$	15,733,650		$	(9,645,706	)	$	6,197,977
Shares issued to CEO		-		-		-						-
Shares issued to employee		1,000		1		169						170
Shares issued for services		1,338,000		1,338		177,482						178,820
Vesting of options and shares issued to officers, directors, advisory board members, consultants and employees						928,832						928,832
Net loss									(2,854,316	)		(2,854,316	)
Balance at September 30, 2013		111,372,282		111,372		16,840,133			(12,500,022	)		4,451,483
The accompanying notes are an integral part of the financial statements

4

 MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

							11-Apr-07
							(Inception Date)
	Nine Months Ended September 30,						to September 30,
	2013			2012			2013
Cash Flows from Operating Activities
Net loss	$	(2,854,316	)	$	(2,896,286	)	$	(12,500,022	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		25,553			771			27,002
Amortization		-			49,451			80,000
Stock based compensation		1,042,793			707,143			4,390,162
Loss on debt conversion		-			760,566			760,566
Impairment charges		-			-			2,662,000
Accounts payable paid in stock		-			7,500			-
Interest expense paid in stock		-			43,762			43,762
Related parties paid in stock		-			71,706			-
Derivatives charges and credits		22,050			(176	)		(1,521,483	)
Changes in operating assets and liabilities
(Increase) decrease in accounts receivable		(13,161	)		(198,042	)		(214,740	)
(Increase) decrease in inventories		207,448			341,538			(10,869	)
(Increase) decrease in prepaid expenses and other assets		(84,425	)		87,546			(125,994	)
Increase (decrease) in accounts payable and accrued expenses		(95,342	)		(363,175	)		25,365
Net cash used in operating activities		(1,749,400	)		(1,387,696	)		(6,384,251	)
Cash Flows from Investing Activities
Acquisition of intellectual property		-			-			(450,000	)
Acquisition of fixed assets		(345,121	)		(2,044	)		(354,959	)
Acquisition of intangible assets		(1,677	)		-			(38,117	)
Decrease in security deposits		-			10,000			-
Net cash used in investing activities		(346,798	)		7,956			(843,076	)
Cash Flows from Financing Activities
(Repayments to) advances from related parties		-			-			140,434
Note borrowings		-			-			19,500
Repayment of notes payable		-			(350,000	)		(807,500	)
Proceeds from (Repayments of) issuance of notes		-			(40,500	)		540,000
Proceeds from issuance of stock to initial stockholders		-			-			80,000
Proceeds from exercise of warrants		-			11,667			11,667
Proceeds from private placement of common stock		-			6,869,990			9,350,490
Offering costs		-			(178,800	)		(223,800	)
Net cash provided by financing activities		-			6,312,357			9,110,791
Net increase/(decrease)  in cash		(2,096,198	)		4,932,617			1,883,464
Cash at beginning of the period		3,979,662			61,266			-
Cash at end of the period	$	1,883,464		$	4,993,883		$	1,883,464

The accompanying notes are an integral part of the financial statements

5

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

CONSOLIDATED STATEMENTS OF CASH FLOW (Continued)

(Unaudited)

					April 11, 2007
					(Inception Date)
	Nine months ended September 30,				to September 30,
	2013		2012		2013
Supplemental Disclosure of Cash Flow Information:
Total Cash paid for franchise taxes	$	2,650	$	2,578	$	6,028
Total Cash paid for Interest	$	10	$	15,892	$	15,902
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Offering costs paid by stockholder	$	-	$	-	$	25,000
Conversion of stockholder loan and interest into common stock	$	-	$	546,743	$	549,487
Conversion of stockholder loan into capital - no shares issued	$	-	$	-	$	22,256
Conversion of 488,331 warrants into 97,669 common shares	$	-	$	44,050	$	44,050
Conversion of 7,529,999 warrants into 1,506,004 common shares	$	-	$	722,882	$	722,882
Note payable - insurance financing	$	-	$	-	$	42,500
Note issued for accounts payable	$	-	$	-	$	7,500
Acquisition of intellectual property through note payable	$	-	$	-	$	700,000
Financing costs through issuance of restricted common stock	$	-	$	20,000	$	80,000

The accompanying notes are an integral part of the financial statements

6

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

NOTE 1 – NATURE OF ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization & Business Activities

MYOS Corporation, formerly known as Atlas Therapeutics Corporation (the "Company") was incorporated under the laws of the State of Nevada on April 11, 2007.  On February 25, 2011, the Company entered into an agreement to purchase certain intellectual property from Peak Wellness, Inc. (the "Acquisition") (see Note 8 - Intellectual Property Purchase Agreement). Since the Acquisition, the Company’s business focus has been on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.  The Company has only realized revenues of $2,921,489 through September 30, 2013 without fully implementing its plan of operations and therefore is still considered a development stage company.

Depreciation

The cost of property and equipment is depreciated over the estimated useful life of 3 to 7 years.  Depreciation is computed using the straight-line method when assets are placed in service. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals.

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles and include the accounts of the Company and its wholly-owned subsidiary, Atlas Acquisition Corp. (formed on February 23, 2011 to facilitate the purchase of the intellectual property discussed in Note 8 - Intellectual Property Purchase Agreement).  All material intercompany balances and transactions have been eliminated.  These financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be a cash equivalent.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.

Fair Value of Indefinite-Lived Intangible Assets

The Company accounts for indefinite-lived intangible assets in accordance with ASC 350, Intangibles-Goodwill and Other.  In accordance with ASC 350, indefinite-lived intangible assets are subject to an impairment analysis at least annually, and more frequently upon the occurrence of certain events.  The impairment analysis is performed by comparing the fair value of the assets with the carrying value of the assets.  Fair value is estimated as the discounted value of future revenues arising from the use of such assets.  An impairment charge is recorded if the assets carrying value exceed the assets estimated fair value.

The Company's policy is to evaluate indefinite-lived intangible assets (e.g. the intellectual property) for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was $2,000,000.  Management performed their quarterly review of the intellectual property and determined no impairment existed and there was no change to the carrying value for the nine months ended September 30, 2013.

Revenue Recognition

The Company recognizes revenue when products are shipped and collection is reasonably assured.

7

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

Inventories

Inventory consist of the following:
	September 30,		December 31,
	2013		2012
Raw materials	$	10,869	$	213,848
Work in process		-		-
Finished goods		-		4,469
Total Inventory	$	10,869	$	218,317

Inventories are stated at the lower of cost or market, with cost determined on a first in, first-out basis.

Advertising

The Company charges the costs of advertising to expense as incurred. The Company incurred $924,368 and $260,427 of advertising and promotional costs for the nine months ended September 30, 2013 and 2012 respectively, and $1,518,930 since its inception.  Pursuant to its distribution agreement with Maximum Human Performance (“MHP”), entered into on May 16, 2012, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold (See Note 10 - Commitments, Contingencies and Other Comments - Distribution Agreement).

Fixed Assets

Fixed assets consist of the following:
	September 30, 2013			December 31, 2012
Furniture, fixtures and equipment	$	100,758		$	3,024
Computers and software		15,247			6,814
Leasehold improvements		233,954			-
Other		5,000			-
Total fixed assets		354,959			9,838
Less accumulated depreciation		(27,000	)		(1,449	)
Net book value of fixed assets	$	327,959		$	8,389

Repair and maintenance costs are expensed as incurred.  Depreciation expense was $25,553 and $771 for the nine months ended September 30, 2013 and 2012, respectively.

Concentrations of Risk, Significant Distributor and Customer and Significant Supplier

The Company maintains its bank accounts with a high credit quality financial institution and has never experienced any losses related to these bank accounts.  From December 31, 2010 through December 31, 2012, all non-interest-bearing transaction accounts were fully insured by the FDIC, regardless of the balance of the account and the ownership capacity of the funds, and interest bearing accounts were insured up to $250,000.  Beginning 2013, insurance coverage reverted back to $250,000 per depositor at each financial institution.  The Company had two noninterest-bearing checking accounts and one interest-bearing savings account which totalled $1,882,714 as of September 30, 2013.   At September 30, 2013, the Company's uninsured cash balances totalled $1,632,714.

Effective May 2012, MHP became the exclusive distributor and sole customer of the Company's MYO-X product and formula (see Note 10 - Commitments, Contingencies and Other Comments – Distribution Agreement).  MHP's exclusivity expired in September 2013.  While the distribution agreement otherwise remains in effect,  the parties are currently negotiating a new agreement.

The Company currently relies on one foreign company to produce the raw product for MYO-T12 (see Note 10 - Commitments, Contingencies and Other Comments – Supply Agreement).  The Company is considering other supply alternatives.

Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees.  ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model.  For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures

8

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation.  Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables.  These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.  

Equity-based compensation expense for awards to employees and non-employees was $1,042,793 and $707,143 for the nine month periods ended September 30, 2013 and 2012, respectively.

Comprehensive Loss

The Company had no items of other comprehensive income or expense for the nine month periods ended September 30, 2013 and 2012.  Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.

Research and Development

The Company incurred $398,199 and $18,279 of research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 and 2012 respectively, and $605,020 since its inception. 

Segment Information

ASC 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information regarding operating segments in annual consolidated financial statements and requires selected information for those segments to be presented in financial reports issued to stockholders.  It also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The Company operates in a single segment, internally reports the results of operations for that segment and the information disclosed herein materially represents all of the financial information related to the single operating segment.

Fair Value Measurement

The Company adopted the provisions of ASC 820 Fair Value Measurements and Disclosures on January 1, 2009.  ASC 820 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.  Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy.  It does not require any new fair value measurements.  It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

Valuation techniques considered under ASC 820 techniques are based on observable and unobservable inputs.  The ASC classifies these inputs into the following hierarchy:

Level 1 inputs are observable inputs and use quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date and are deemed to be most reliable measure of fair value.

Level 2 inputs are observable inputs and reflect assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity.  Level 2 inputs includes 1) quoted prices for similar assets or liabilities in active markets, 2) quoted prices for identical or similar assets or liabilities in markets that are not active, 3) observable inputs such as interest rates and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, credits risks, default rates, and 4) market-corroborated inputs.

Level 3 inputs are unobservable inputs and reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

In October 2008, the FASB clarified the application of ASC 820 in determining the fair value of a financial asset when the market for that financial asset is not active.

The Company adopted the provisions of ASC 825, The Fair Value Option for Financial Assets and Liabilities, on January 1, 2009.  ASC 825 permits us to choose to measure certain financial assets and liabilities at fair value that are not currently required to be measured at fair value (the “Fair Value Option”).  Election of the Fair Value Option is made on an instrument-by-instrument basis and is irrevocable.  At the adoption date, unrealized gains and losses on financial assets and liabilities for which the Fair Value Option has been elected are reported as a cumulative adjustment to beginning retained earnings.

Our intangible assets are valued and tested for impairment using Level 3 inputs (see Note 8 - Intellectual Property Purchase Agreement).  In the process of the valuation of the intangible asset, we determined that the carrying cost exceeded the fair value at December 31, 2011 and we recorded an impairment charge and adjusted the balance of the asset to reflect the fair value.  There were no impairment charges for any subsequent periods.

9

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

Basic and Diluted Income (Loss) per Share

In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding.  Diluted loss per common share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At September 30, 2013 and 2012, the Company’s stock equivalents were anti-dilutive and excluded in the diluted loss per share computation.  The aggregate number of potentially dilutive options and warrants outstanding at September 30, 2013 and 2012 were 11,091,000 and 1,650,000, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.

The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement.  This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements.  It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions.  The Company has no uncertain income tax positions.

Interest costs and penalties related to income taxes are classified as interest expense and selling, general and administrative costs, respectively, in the Company's financial statements.  For the nine months ended September 30, 2013 and 2012, the Company did not recognize any interest or penalty expense related to income taxes.  The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

NOTE 2 - PRIVATE PLACEMENTS OF RESTRICTED COMMON STOCK

During April 2007, the Company sold 28,000,000 (after adjusting for the 1 to 14 split) shares of its common stock to its founders for cash proceeds of $5,000.  During December 2007, the Company sold 21,000,000 (after adjusting for the 1 to 14 split) shares of its common stock in a private placement for cash proceeds of $75,000.

From February 25 through July 12, 2011, the Company issued an aggregate of 8,134,997 shares of common stock and warrants to purchase 8,134,997 shares of common stock to certain accredited investors (the “Private Placements”) with piggy-back registration rights.  Each warrant had a three-year term and was exercisable at $0.10 per share (due to the triggering of a down round full ratchet anti dilution provision).  In June and September 2012, 8,018,330 of warrants were exchanged for 1,603,673 shares of the Company's common stock and 116,667 warrants were exercised for $11,667.

On December 2, 2011, one accredited investor purchased 200,000 shares for gross proceeds of $40,000 in a private placement.  The subscription agreement contained a "Purchase Price Protection" provision that granted the investor additional shares in the event of a private placement during the ten month period from the date of the investment at a price per share less than the investor's purchase price.  The additional shares were to be issued for no additional payment such that the total per share price paid by this investor will equal the amount paid by investors in such later private placement.  In April 2012, the Company issued an additional 200,000 shares to the investor as a result of the price protection provision.

During February and March 2012, the Company issued an aggregate of 10,250,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $1,025,000.  The securities are subject to piggyback registration rights.

In April 2012, the Company issued an aggregate of 1,000,000 shares of restricted common stock to one accredited investor in a private placement and received aggregate gross proceeds of $100,000.  The securities are subject to piggyback registration rights.

10

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

In June 2012, the Company issued an aggregate of 2,400,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $600,000.  The securities are subject to registration rights.

In July 2012, the Company issued an aggregate of 20,580,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $5,144,990.  The securities are subject to registration rights.

The Company received aggregate gross proceeds of $9,350,490 from the private placements as follows:

Date	Shares		Gross Proceeds		Related Warrant Liability at Inception		Related Warrant Liability at September 30, 2013
February 25, 2011		4,766,666	$	1,430,000	$	2,350,251	$	-
May 31, 2011		1,409,999		423,000		1,186,859		-
June 27, 2011		1,874,999		562,500		1,243,838		-
July 12, 2011		83,333		25,000		57,742		-
December 2, 2011		200,000		40,000		-		-
February 10, 2012		3,250,000		325,000		-		-
February 14, 2012		4,000,000		400,000		-		-
March 7, 2012		1,000,000		100,000		-		-
March 15, 2012		1,750,000		175,000		-		-
March 22, 2012		250,000		25,000		-		-
April 9, 2012		1,000,000		100,000		-		-
April 24, 2012		* 200,000		-		-		-
June 28, 2012		2,400,000		600,000		-		-
July 6, 2012		20,580,000		5,144,990		-		-
		42,764,997	$	9,350,490	$	4,838,690	$	-

* Shares issued under price protection provision of subscription agreement as described above.

The warrants were subject to full ratchet anti-dilution protection if the Company sold shares or share-indexed financing instruments at less than the $0.60 exercise price.  Repricing events occurred twice while the warrants were issued, once to $0.20 on December 2, 2011 and again to $0.10 on February 10, 2012 as a result of private placements of restricted common stock.  The warrants issued in this financing arrangement did not meet the conditions for equity classification and were required to be carried as a derivative liability, at fair value.  Management estimated the fair value of the warrants on the inception dates, and subsequently at each reporting period, using the Black-Scholes option-pricing model, adjusted for dilution, because that technique embodies all of the assumptions (including volatility, expected terms, dilution and risk free rates) that are necessary to determine the fair value of freestanding warrants.

On June 27, 2012, holders of an aggregate of 7,529,999 warrants exchanged those warrants for 1,506,004 shares of common stock.

On September 24, 2012, holders of an aggregate of 488,331 warrants exchanged those warrants for 97,669 shares of common stock.

On September 24, 2012, a holder of 116,667 warrants exercised those warrants at $0.10 a share and received 116,667 shares of common stock.

NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not believe that the adoption of any recently issued, but not yet effective, accounting standards will have a material effect on its financial position and results of operations.

NOTE 4 - ADVANCES, ACCOUNTS PAYABLE AND ACCRUED EXPENSES -  RELATED PARTIES

As of September 30, 2013 and December 31, 2012, there are no amounts due to related parties for advances, accounts payable and accrued expenses.

11

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

NOTE 5 - NOTES AND LOANS PAYABLE

Convertible Notes Payable

On November 29, 2011, the Company received aggregate proceeds of $400,000 from two individuals ($150,000 of which was from a director of the Company) on notes payable bearing interest at 18%, due on May 29, 2012 and convertible into common stock at the rate of $0.20 per share or an adjusted lower rate determined by reference to a subsequent qualified financing.  As additional consideration, the note holders were issued an aggregate of 400,000 shares of common stock valued at $0.15 per share for an aggregate of $60,000.  The value of the shares issued were recorded as deferred financing costs and were amortized over the six month term of the notes.  There were no unamortized balances at September 30, 2013 and December 31, 2012, respectively.  Related amortization expense was $34,000 for the nine months ended September 30, 2012.

On June 28, 2012, the aggregate principal of $400,000 and the accrued interest of $41,800 on the notes were converted into 2,209,000 shares of restricted common stock at $0.20 per share, the value of which exceeded the principal and accrued interest by $618,520 on the conversion date.  This amount was recorded as interest expense in the second quarter of 2012.  The amount recorded as interest expense for the nine months ended September 30, 2012 was $654,123.

Notes Payable to Director

A director loaned the Company $99,500, of which $60,000 was advanced on September 29, 2011 and was evidenced by an unsecured note payable which was due on October 29, 2011 bearing interest at 3%; $10,000 was advanced in October 2011; $10,000 was advanced in December 2011 for direct payment to a vendor and $19,500 of which was advanced in January 2012 for direct payments to vendors.  On June 28, 2012, the principal plus accrued interest on the loans and advances of $1,961 (aggregate of $101,461) were converted into 507,306 shares of common stock at $0.20 per share, the value of which exceeded the principal and accrued interest by $142,046 on the conversion date.  This amount was recorded as interest expense in the second quarter of 2012.  The amount recorded as interest expense for the nine months ended September 30, 2012 was $143,557.

Note Payable to Shareholders

On May 20, 2010, the Company issued a note for $7,500 bearing interest at 5% in exchange for a shareholder's payment of $7,500 on an open account payable balance. The note was due and payable upon demand.  On September 20, 2012, the aggregate principal and accrued interest  were converted into 30,000 shares of restricted common stock. The amount recorded as interest expense for the nine months ended September 30, 2012 was $188.

On June 15, 2012, a stockholder loaned the Company $65,000, payable on July 15, 2012 without interest.  The loan was repaid in July 2012.

NOTE 6 - CAPITAL STOCK

On February 12, 2010, the Company’s articles of incorporation were amended to increase the number of authorized preferred shares to 25,000,000 and the number of authorized common shares to 300,000,000. The Company’s 3,500,000 common shares outstanding were also forward split on a 14 shares for 1 basis with the result that 49,000,000 shares were issued and outstanding on that date. The accompanying financial statements reflect the forward stock split on a retroactive basis.

NOTE 7 - WARRANTS, OPTIONS, EQUITY INCENTIVE PLAN AND STOCK ISSUANCES

Warrants

During the year ended December 31, 2011, the Company issued a total of 8,284,997 warrants to purchase restricted common stock.  Of those warrants, 8,134,997 were issued to private placement investors and included down round full ratchet anti-dilution provisions requiring periodic repricing if shares are later offered at lower prices.  In June 2012, holders of 7,529,999 warrants received 1,506,004 shares of restricted common stock in exchange for those warrants.  In September 2012, holders of 488,331 warrants received 97,669 shares of restricted common stock in exchange for such warrants and a holder of 116,667 warrants exercised such warrants at $0.10/share and received 116,667 shares of restricted common stock. During the year ended December 31, 2012 and nine months ended September 30, 2013, no warrants were issued. 

12

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The following table summarizes the total warrants issued to private placement investors and consultants.    During the nine months ended September 30, 2013, no warrants were issued.  Derivative charges were $22,050 and ($177) for the nine months ended September 30, 2013 and 2012, respectively. The number of warrants outstanding as of September 30, 2013 is 50,000.

Grant Date	Number of Warrants Issued		Number of Warrants Exchanged, Exercised or Expired		Number of Warrants Outstanding as of September 30, 2013	Exercise Price Original/Repriced		Expiration Term in Years
February 25, 2011 (A)		4,766,666		4,766,666	-	$	0.60/$0.10	-
May 31, 2011  (A)		1,409,999		1,409,999	-	$	0.60/$0.10	-
June 27, 2011  (A)		1,874,999		1,874,999	-	$	0.60/$0.10	-
June 27, 2011 (B)		100,000		100,000	-	$	1.00	-
July 12, 2011  (A)		83,333		83,333	-	$	0.60/$0.10	-
December 23, 2011  (B)		50,000		-	50,000	$	1.00	.23

(A) Private placement warrants (these warrants were subject to down round full ratchet anti dilution provisions and the exercise price was adjusted to $0.10 per share in February 2012)

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

The following table summarizes the activities in warrants for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Warrants			Weighted Average Exercise Price Original/Repriced
Balance at January 1, 2012		8,284,997		$	0.61/$0.10
Warrants granted		-
Warrants exercised		(116,667	)
Warrants cancelled/exchanged/expired		(8,018,330	)
Balance at December 31, 2012		150,000		$	1.00
Warrants granted		-
Warrants exercised		-
Warrants cancelled/exchanged/expired		100,000		$	1.00
Balance at September 30, 2013		50,000		$	1.00

The following table summarizes information about warrants outstanding and exercisable at September 30, 2013.  As all warrants currently outstanding are fully and immediately vested at issuance, the information for both outstanding and exercisable are identical.

Warrants Outstanding and Exercisable
Range of Exercise Price		Warrants Outstanding and Exercisable	Weighted Average Remaining Contractual Life
$	1.00	50,000	.23

The following table summarizes the assumptions used to value the warrants using the Black-Scholes option pricing model:

Grant Date		Number of Warrants Issued/ Outstanding		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
(A)	02/25/11		4,766,666	$	0.50	$	0.60		3.00		285.20	%		0.00	%		1.48	%
(A)	05/31/11		1,409,999	$	0.85	$	0.60		3.00		208.89	%		0.00	%		0.79	%
(A)	06/27/11		1,874,999	$	0.67	$	0.60		3.00		295.31	%		0.00	%		0.64	%
(A)	07/12/11		83,333	$	0.70	$	0.60		3.00		278.00	%		0.00	%		0.42	%
(B)	06/27/11		100,000	$	0.67	$	1.00		2.00		213.59	%		0.00	%		0.41	%
(B)	12/23/11		50,000	$	0.09	$	1.00		2.00		209.00	%		0.00	%		0.28	%

(A) Private placement warrants

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

13

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

Options

The Company has issued an aggregate of 1,500,000 options to purchase restricted common stock to certain directors and scientific advisory board members (see Note 10 - Commitments, Contingencies and Other Comments – Director Agreements) prior to the adoption of the 2012 Equity Incentive Plan (the “Plan”).  For options issued under the Equity Incentive Plan, see “Equity Incentive Plan” below.

The following table summarizes the activities in stock options (outside the Plan) for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Options		Weighted Average Exercise Price
Balance at January 1, 2012		1,250,000	$	0.61
Options granted		250,000	$	0.14
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		1,500,000	$	0.53
Options granted		-
Options exercised		-
Options cancelled/expired		-
Balance at September 30, 2013		1,500,000	$	0.53

At September 30, 2013, the weighted-average remaining term of the options was 7.95 years.  As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was $NIL.  The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option.  The market price for our common stock at September 30, 2013 was $0.12.  The aggregate unvested cost of the options at September 30, 2013 was $79,861.

The following table summarizes the assumptions used to value the director/advisory board options using the Black-Scholes option pricing model:

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
07/14/11		750,000	$	0.64	$	0.64		10.00		287.00	%		0.00	%		2.98	%
07/26/11		250,000	$	0.69	$	0.69		10.00		285.00	%		0.00	%		2.99	%
08/15/11		250,000	$	0.45	$	0.45		10.00		284.00	%		0.00	%		2.29	%
05/24/12		250,000	$	0.14	$	0.14		10.00		187.00	%		0.00	%		1.77	%

14

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The following table summarizes information about the options (outside the Plan) outstanding and exercisable at September 30, 2013 by the directors and scientific advisory board members:

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.64		750,000		7.79	$	0.64		625,000		7.79
$	0.69		250,000		7.82	$	0.69		250,000		7.82
$	0.45		250,000		7.87	$	0.45		250,000		7.87
$	0.14		250,000		8.65	$	0.14		166,666		8.65

As of September 30, 2013, 1,291,666 options have vested and 208,334 options remain unvested. The vesting terms range from 3 to 4 years and the vested options have a weighted average remaining term of 7.92 years and a weighted average exercise price of $0.55 per share.

Equity Incentive Plan

On September 24, 2012, the Company’s board of directors adopted the 2012 Equity Incentive Plan (the "Plan"), which was adopted by stockholders on November 20, 2012.  The Company believes that such awards better align the interests of its employees and directors with those of its shareholders.  The Company has reserved 10,000,000 shares of common stock under the Plan.  As of September 30, 2013, options to purchase 9,541,000 shares of the Company's stock have been granted under the Plan, as set forth in the table below:

Issued to	Number of Options		Range of Exercise Price		Expiration Term in Years
Employees		112,000	$	0.20 to 0.25	10
Consultants		1,327,000	$	0.20 to 0.25	10
Officers		1,152,000	$	0.20 to 0.25	10
Directors		6,700,000	$	0.14 to 0.35	10
Scientific Advisory Board Member		250,000	$	0.25	10
Total		9,541,000

The fair value of each option award is estimated on the date of grant using a Black Scholes model that uses variables noted in the following table.  Our determination of fair value is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury 10-year note in effect at the time of the grant.

The following table summarizes the assumptions used to value the Plan options using the Black-Scholes option pricing model:

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
11/20/12		6,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.66	%
01/01/13		150,000	$	0.19	$	0.22		10.00		164.00	%		0.00	%		2.00	%
01/07/13		350,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.92	%
01/07/13		2,000,000	$	0.20	$	0.25		10.00		166.00	%		0.00	%		1.92	%
02/07/13		5,000,000	$	0.20	$	0.35		10.00		164.00	%		0.00	%		1.99	%
02/07/13		450,000	$	0.20	$	0.25		10.00		164.00	%		0.00	%		1.99	%
02/08/13		250,000	$	0.19	$	0.20		10.00		164.00	%		0.00	%		2.00	%
02/28/13		100,000	$	0.20	$	0.25		10.00		158.00	%		0.00	%		1.89	%
04/01/13		150,000	$	0.14	$	0.14		10.00		160.00	%		0.00	%		1.86	%
05/06/13		400,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.80	%
05/20/13		10,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.97	%
05/21/13		200,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.94	%
05/24/13		5,000	$	0.13	$	0.25		10.00		160.00	%		0.00	%		2.01	%
06/10/13		100,000	$	0.16	$	0.25		10.00		160.00	%		0.00	%		2.22	%
07/01/13		150,000	$	0.19	$	0.19		10.00		159.00	%		0.00	%		2.50	%
08/21/13		220,000	$	0.17	$	0.25		10.00		157.00	%		0.00	%		2.87	%

15

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The following table summarizes the activities in stock options issued under the Plan during 2012 and during the nine month period ended September 30, 2013:

	Shares Under Options			Weighted Average Exercise Price
Balance at January 1, 2012		-
Options granted		8,000		$	0.20
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		8,000		$	0.20
Options granted		9,535,000		$	0.30
Options exercised		-
Options cancelled/expired		(2,000	)	$	0.20
Balance at September 30, 2013		9,541,000		$	0.30

At September 30, 2013, the weighted-average remaining term of the options was 9.38 years.  As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was $NIL.  The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option.  The market price for our common stock at September 30, 2013 was $0.12.  The aggregate unvested cost of the options at September 30, 2013 was $1,116,174.

The following table summarizes information about options outstanding and exercisable at September 30, 2013 that were granted under the Plan:

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.14		150,000		9.51	$	0.14		-		-
$	0.19		150,000		9.76	$	0.19		-		-
$	0.20		606,000		9.31	$	0.20		159,333		9.32
$	0.22		150,000		9.28	$	0.22		-		-
$	0.25		3,485,000		9.40	$	0.25		358,332		9.29
$	0.35		5,000,000		9.36	$	0.35		-		-

As of September 30, 2013, 517,665 options have vested and 9,023,335 options remain unvested.  The vesting terms range from zero to 5 years and the vested options have a weighted average remaining term of 9.30 years and a weighted average exercise price of $0.23 per share.

Stock Issuances

During the year ended December 31, 2012, the Company issued an aggregate of 4,183,395 shares of restricted common stock to consultants, a director, an employee and officers for services provided to the Company.  The shares issued were valued at trading prices on the date of issuance between $0.07 and $0.45 per share.  The compensation cost as a result of the issuance and vesting of such shares are aggregate charges of $40,337 and $445,063 for the nine month periods ended September 30, 2013 and 2012, respectively.  The shares issued to one of our officers and a director are subject to certain vesting requirements.

During the nine months ended September 30, 2013, the Company issued an aggregate of 1,339,000 shares of restricted common stock to a director, an employee and consultants.  All such shares were valued at trading prices on the date of issuance between $0.12 and $0.20 per share,  The compensation cost as a result of the issuance and vesting of such shares is an aggregate charge of $94,549 for the nine month period ended September 30, 2013.  Additionally, on January 7, 2013, the Company issued 5,000,000 shares to an officer which were subsequently cancelled in April 2013 upon the termination of his employment with the Company.

16

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

NOTE 8 – INTELLECTUAL PROPERTY PURCHASE AGREEMENT

On February 25, 2011, the Company, Atlas Acquisition Corp., a wholly-owned subsidiary of the Company formed in February 2011 (“Atlas Sub”), and Peak Wellness, Inc. (“Peak”), entered into and consummated an Intellectual Property Purchase Agreement (the “Purchase Agreement”), pursuant to which Atlas Sub purchased certain intellectual property assets from Peak (the “Acquisition”).  Pursuant to the Purchase Agreement, the Company acquired from Peak all intellectual property pertaining to MYO-T12, a natural-myostatin inhibitor, including the formula and process for making MYO-T12, certain trademarks, trade secrets, patent applications and certain domain names.  The aggregate consideration for MYO-T12 was $4,662,000 paid in cash, a promissory note and shares of common stock. The contractually stated purchase price for the assets was $1,150,000, of which $450,000 was paid in cash and $700,000 via the issuance of the promissory note.  Additionally, the Company issued 7,024,000 shares of common stock with an aggregate fair value of $3,512,000 to Peak as part of the purchase price of MYO-T12, representing 12% of the fully diluted voting common stock of the Company on the date of the Acquisition.

In connection with the Purchase Agreement, the Company issued a secured promissory note to Peak (the “Promissory Note”) in the amount of $700,000 with interest accruing at an interest rate of 3% per annum.  The Promissory Note was payable in two installments as follows: $350,000 plus accrued interest was due within 180 days after the closing date of the Agreement (originally August 25, 2011 but extended to the earlier of November 30, 2011 or the closing of a certain financing and paid on November 29, 2011) and $350,000 plus accrued interest was due on the first anniversary of the closing date of the Agreement and paid on February 21, 2012.

In connection with the Purchase Agreement and the Promissory Note, the Company entered into a security agreement with Peak to secure the payments due under the Promissory Note (the “Security Agreement”).  Pursuant to the Security Agreement, the Company granted Peak a continuing security interest in the assets purchased from Peak. The Security Agreement also secured all of the Company’s obligations to Peak, whether related or unrelated to the Promissory Note. The security interest was released in February 2012 upon payment of the final installment of the Promissory Note.  On the closing date of the Acquisition, new officers and a new director were appointed to serve the Company.

The Company completed its first annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011. Based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues from sales of MYO-T12 and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property intangible assets exceeded its fair value.  Accordingly, the Company recorded noncash impairment charges totaling $2,662,000 in 2011, reducing the MYO-T12 intellectual property asset to its fair value of $2,000,000.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was $2,000,000.  Management performed their annual and quarterly reviews of the intellectual property and determined no impairment existed and there was no change to the carrying value for the year ended December 31, 2012 and the nine months ended September 30, 2013, respectively.

NOTE 9 - INCOME TAXES

Income tax expense for the nine months ended September 30, 2013 and 2012 is shown as follows:

Nine months ended September 30,	2013		2012
Current	$	1,300	$	1,550
Deferred		-		-
Total	$	1,300	$	1,550

17

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The effects of temporary differences between the financial reporting and income tax bases of assets and liabilities which give rise to the deferred tax assets and liabilities are presented below:

	September 30,  2013			December 31, 2012
Deferred tax assets:
Goodwill	$	588,015		$	672,348
Net operating losses		3,104,230			2,133,004
Other		1,582			1,542
Total deferred tax assets		3,693,827			2,806,894
Valuation allowance		(3,681,438	)		(2,804,632	)
Total net deferred tax assets		12,389			2,262
Deferred tax liabilities:
Depreciation		(12,389	)		(2,262	)
Total deferred tax liabilities		(12,389	)		(2,262	)
Net deferred tax asset	$	-		$	-

The valuation allowance for the deferred tax asset increased by $876,806 for the nine months ended September 30, 2013.

The Company has net operating losses amounting to approximately $7,891,134 that expire in various periods through 2033.  The ultimate realization of the net operating losses is dependent upon future taxable income, if any, of the Company and may be limited in any one period by alternative minimum tax rules.  Although management believes that the Company will have sufficient future taxable income to absorb the net operating loss carryovers before the expiration of the carryover period, the current global economic crisis imposes additional profitability risks that are beyond the Company’s control.  Accordingly, management has determined that a full valuation allowance of the deferred tax asset is appropriate at this time.

Internal Revenue Code Section 382 imposes limitations on the use of net operating loss carryovers when the stock ownership of one or more 5% shareholders (shareholders owning 5% or more of the Company’s outstanding capital stock) has increased by more than 50 percentage points.  Management intends to carefully monitor share ownership of 5% shareholders but cannot control the ownership changes occurring as a result of public trading of the Company’s Common Stock.  Accordingly, there is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover.

The Company has no uncertain income tax positions.

The tax years ended December 31, 2007 through 2012 are open for examination by federal and state taxing authorities.

The statutory federal income tax rate and the effective rate are reconciled as follows:

	September 30, 2013			September 30, 2012
Statutory federal income tax rate		34.00	%		34.00	%
State taxes, net of federal tax benefit		5.94	%		5.00	%
Valuation allowance		(39.94	)%		(39.00	)%
Net deferred tax asset		-	%		-	%

18

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

NOTE 10 - COMMITMENTS, CONTINGENCIES AND OTHER COMMENTS

Distribution Agreement

On May 16, 2012, the Company entered into a distribution agreement (the "Agreement") with MHP, a company engaged in the development, marketing and distribution of nutritional and other therapies for the consumer.  Pursuant to the Agreement, MHP will, on an exclusive basis, provide marketing, sales and distribution of MYO-T12, to be sold under the brand name MYO-X, in retail and other outlets.  MHP agreed to pay the Company $195,301 upon the execution of the Agreement, with such amount credited against inventory purchases.  The Agreement also provides, upon termination of MHP's exclusivity rights, additional supply and payment rights to MHP (including a per-unit royalty in the low single digits).  The Agreement provided for one year of exclusivity for MHP, which expired on September 29, 2013.  While the Agreement remains in effect, the parties are currently negotiating a new agreement.  The Agreement further provides for a co-operative advertising arrangement with MHP, whereby the Company is required to pay MHP a fee for each unit of MYO-X sold, and rebate payments to MHP based on a percentage of product cost reductions realized by the Company.

Bank Line of Credit

In October 2013, the Company was granted a $500,000 line of credit by City National Bank, that bears a per annum interest rate through April 15, 2014 equal to the prime rate, after which the rate changes to the prime rate plus 1.25 percent.  As of the date of this report, the Company has not drawn on the line of credit.

Operating Lease

The Company leases its corporate offices under an operating lease expiring in July 2017.  The Company has two options to renew such lease for a term of three years each with annual rent increases of 3%.

The future minimum lease payments under the non-cancellable operating lease in excess of one year at September 30, 2013 is as follows:

Year Ending December 31,	Amount
2013	$	14,042
2014		59,434
2015		65,095
2016		67,163
2017		39,623
Total	$	245,357

Rent expense for the nine months ended September 30, 2013 and 2012 was $44,018 and $22,155, respectively.

Supply Agreement

On June 24, 2013, the Company entered into a supply agreement with Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”).  The agreement obligates the Company to minimum annual quantity purchases, and provides that DIL will manufacture and supply the Company with the proprietary product contained in MYO-X and that DIL shall only manufacture the product for commercial purposes with the Company’s consent.  The term of the agreement is for two years, and will continue indefinitely until terminated by either party upon three months written notice.

Employment Agreements

J.B. Bernstein:

On February 25, 2011, the Company entered into an employment agreement with J.B. Bernstein, pursuant to which Mr. Bernstein served as Chief Executive Officer of the Company.  The employment agreement was amended effective as of March 1, 2011.  On April 30, 2012, J.B. Bernstein resigned from his positions as President and Chief Executive Officer and as a member of the Company’s board of directors.  In connection with his resignation, Mr. Bernstein entered into a consulting agreement with the Company (the “Consulting Agreement”), pursuant to which Mr. Bernstein was entitled to a consulting fee of $5,000 per month during the six-month term of the Consulting Agreement, which expired on October 31, 2012.  The Consulting Agreement also included confidentiality and non-competition obligations and provisions for intellectual property assignments by Mr. Bernstein.

Carlon Colker MD, FACN:

On February 25, 2011, concurrent with the closing of the Acquisition, the Company entered into an employment agreement with Carlon Colker, MD, FACN, pursuant to which Dr. Colker agreed to serve as Chief Medical Officer and Executive Vice President of the Company.  On June 14, 2012, Dr. Carlon Colker resigned from his positions as Chief Medical Officer and Executive Vice President.  Simultaneously with his resignation, Dr. Colker agreed to serve on the Company’s Scientific Advisory Board.  In connection with his appointment to the Scientific Advisory Board, Dr. Colker entered into an advisory board agreement with the Company, pursuant to which the Company issued him 300,000 shares of common stock.  The Agreement also includes standard confidentiality and non-competition obligations and provisions for intellectual property assignments by Dr. Colker.

19

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

Glen R. Fleischer:

On January 2, 2013, we entered into an employment agreement with Glen R. Fleischer pursuant to which Mr. Fleischer agreed to serve as our Chief Executive Officer and as a member of our board of directors.

Pursuant to the terms of the agreement, Mr. Fleischer would work for us on a full-time basis and receive an annual base salary of $320,000.  Mr. Fleischer was also entitled to an annual cash bonus in an amount up to 100% of his base salary, as determined by our board of directors in its sole discretion. In addition, Mr. Fleischer was granted 5,000,000 shares of our common stock, which shares were to vest in four equal semi-annual installments commencing on July 2, 2013. The term of the agreement was three years, and the agreement was to automatically renew for successive one-year periods, unless a notice of non-renewal was provided by either party at least sixty days prior to the expiration date of the term.  On April 25, 2013, Mr. Fleischer resigned as our Chief Executive Officer and as a member of our board of directors.

Peter A. Levy:

On February 8, 2013, we entered into an amended and restated employment agreement with Peter Levy to continue to serve as our Chief Operating Officer and Executive Vice President. The agreement replaced Mr. Levy’s existing employment agreement dated February 10, 2012.  Pursuant to the terms of the agreement, Mr. Levy will continue to work as Chief Operating Officer and Executive Vice President on a full-time basis and receive an annual base salary of $200,000.    Mr. Levy may receive an annual cash bonus in an amount up to 100% of his base salary, as may be determined by the Board in its sole discretion. The 500,000 shares of common stock previously granted to Mr. Levy will vest in four equal semi-annual installments commencing on August 10, 2012. The term of the agreement is three years, and the agreement will automatically renew for successive one-year periods, unless a notice of non-renewal is provided by either party at least sixty days prior to the expiration date of the term.  

In the event Mr. Levy’s employment is terminated for cause (as defined in the agreement) or as a result of death or disability, or if Mr. Levy terminates his employment without good reason (as defined in the agreement), Mr. Levy will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as retain any shares that have previously vested.

In the event Mr. Levy’s employment is terminated for any reason other than cause, death or disability, or if Mr. Levy terminates his employment for good reason, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as any vested shares. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination.

In the event Mr. Levy’s employment is terminated in connection with, or as a result of, a change of control (as defined in the agreement), or if Mr. Levy terminates his employment for good reason following a change in control, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination. Furthermore, all of his unvested shares will vest as of the date of the consummation of the change in control.

The agreement contains customary non-competition and non-solicitation provisions that extend to two years after termination of Mr. Levy’s employment.  Mr. Levy also agreed to customary terms regarding confidentiality and ownership of product ideas.

On April 21, 2013, Mr. Levy was appointed to the additional position of President of the Company and in such capacity will serve as the Company's Principal Executive Officer.

Sponsorship Agreement

On June 27, 2011, the Company entered into a one year agreement with a celebrity spokesperson pursuant to which the spokesperson agreed to perform certain services for the Company and granted the Company the worldwide right to use the spokesperson’s name and approved image in various media.  The agreement provided for cash compensation of $150,000 in three equal installments of $50,000, all of which was paid in 2011.  Royalties at the rate of $0.50 per unit sold are payable to the spokesperson for the term of the agreement and an additional 12 months thereafter.  The agreement expired in June 2012.

20

MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The agreement also provided for the issuance of warrants to purchase 150,000 shares of common stock, 100,000 of which were issued upon signing of the agreement and 50,000 of which were issued in December 2011.  The warrants have a term of two years with an exercise price of $1.00 per share.  The warrants further provide that in the event (a) the trading price of the common stock of the Company on its principal trading market does not exceed $2.00 within two years of issuance and (b) the warrants are not exercised prior to such time, then the spokesperson shall have the right to sell any unexercised portion of the warrants to the Company in exchange for $1.00 for each share of common stock underlying the unexercised portion of the warrants.

The 100,000 warrants issued upon execution of the agreement and the 50,000 warrants issued in December 2011 were valued at September 30, 2013 at $NIL and $43,950, respectively, using a Black-Scholes option pricing model with the put option as the predominant feature of the instrument.  On June 27, 2013, the 100,000 warrants expired and a $100,000 liability was recorded.

Director Agreements

Dr. Louis Aronne:

On July 14, 2011, the Company entered into two separate agreements with Dr. Louis Aronne to be a member of the Board of Directors and the Scientific Advisory Board.  The director agreement provides for compensation in the form of 100,000 shares of restricted common stock vesting in five equal annual installments commencing on execution of the agreement and an option to purchase 250,000 shares of common stock at an exercise price of $0.64 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option will vest immediately.  The advisory board agreement has a term of 5 years and provides for the issuance of 500,000 shares vesting in five equal annual installments commencing July 14, 2012 and an option to purchase 500,000 shares at $.64 per share vesting in four equal annual installments, and the first installment vested immediately upon the execution of the agreement.  Upon a Change of Control, all unvested option shall immediately vest.

Dr. Robert Hariri:

On July 26, 2011, the Company entered into an agreement with Dr. Robert Hariri to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.69 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option shall immediately vest. 

Dr. Peter Diamandis:

On August 15, 2011, the Company entered into an agreement with Dr. Peter Diamandis to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.45 for 10 years vesting over a period of 3 years,  the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Buzz Aldrin:

On May 24, 2012, the Company entered into an agreement with Dr. Buzz Aldrin to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.14 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Sapna Srivastava:

On February 6, 2013, the Company entered into an agreement with Dr. Sapna Srivastava to serve as a member of the Board of Directors.  The director agreement provides for the issuance of 100,000 shares of restricted common stock, vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock, issued under the Plan, at an exercise price of $0.20 for 10 years vesting over a period of 3 years. The options are subject to the terms and provision of the Plan.

NOTE 11 - SUBSEQUENT EVENTS

NONE

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on  Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2012.

Certain statements in this section contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements contained in this report and not clearly historical in nature are forward-looking, and the words “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) generally are intended to identify forward-looking statements.  Any statements in this report that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Overview

We were incorporated in the State of Nevada on April 11, 2007.  Prior to February 26, 2011, we did not have any operations and did not generate any revenues.  In February 2011, we acquired our platform dietary supplement product called MYO-T12.  Since February 2011, our principal activities have been focused on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.   We are focused on maximizing revenues from MYO-T12 in a consumer base of body builder and fitness users as well as a broader target of wellness focused baby boomers.  Additionally, we are evaluating the value of MYO-T12 in therapeutic markets, including the treatment of muscular-related conditions, including age-related muscle loss and sarcopenia.

Plan of Operation

We are focused on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.  Our initial core product is MYO-T12, a natural, temporary myostatin-inhibiting product.  Our sales are conducted pursuant to our distribution agreement with MHP.  Our plan of action over the next twelve months is to: (i) deepen the scientific understanding of the activity of MYO-T12, specifically as a natural and temporary modulator of the regulatory peptide myostatin, and to leverage this knowledge to strengthen and build our intellectual property, (ii) conduct research and development activities to evaluate myostatin modulation in a range of both wellness and disease states, (iii) identify other products and technologies which may broaden our portfolio and define a business development strategy to protect, enhance and accelerate the growth of our products, (iv) reduce the cost of manufacturing through process improvement, (v) identify contract manufacturing resources that can fully meet our future growth requirements, (vi) develop a differentiated and advantaged consumer positioning, brand name and iconography, and (vii) create a sales and marketing capability through alliances to maximize near-term and future revenues. We believe that existing wellness and therapeutic targets, such as myostatin, represent a rational entry point for additional drug discovery efforts and are evaluating a separate, concurrent objective in this area.

Our distribution agreement with MHP represents a significant shift away from our previous plan to market the product to the consumer as well as to other specialty retail distributors directly.  Instead, we co-brand our product under the MYO-X name and focus on conducting clinical trials of MYO-T12 to support our marketing claims as well as to enhance our intellectual property, to develop product improvements and new products, and to reduce the cost of the product by finding more efficient manufacturing processes and contract manufacturers.  MHP's exclusivity expired in September 2013 and the parties are negotiating a new agreement.

As an early development-stage biotherapeutics and nutritional products company, we are dedicated to basic and clinical research which support our existing and future product portfolio.  We have launched our internal research and development efforts through construction of a dedicated protein chemistry and proteomics laboratory led by Dr. Neerav Padilya.  The Company incurred approximately $49,000 of costs related to the construction of its state-of-the-art research laboratory through the third quarter of 2013 which have been capitalized for future R&D activities.  This laboratory is actively evaluating the many active molecules in our lead product MYO-T12. In addition, the research performed in this laboratory will establish a basis for the continued submission of patent applications to help protect the Company's intellectual property.  The Company is dedicated to protecting its innovative technology.

Additionally, the Company invests in research and development activities externally through academic and industry collaborations aimed at enhancing its products and broadening its product portfolio. The Company is committed to research and development and expects its investment in research and development to continue to grow in the future.

In July 2013, the Company entered into a clinical study agreement with The Brigham and Woman’s Hospital, Inc. to conduct a clinical study on the effects of MYO-T12 alone or in combination with testosterone on skeletal mass and the fat mass in a preclinical rodent model.  This study is expected to be completed in the first quarter of 2014.

In September 2013, the Company entered into a clinical study agreement with Hackensack University Medical Center to conduct a clinical study to determine the effects of MYO-T12 on blood chemistries and body mass index in healthy adult women.  This study is expected to be completed in the first quarter of 2014.

This aforementioned agreements are an integral part of our business strategy and we believe they will provide a clear scientific rationale for MYO-T12's role as a nutritional product and support its use in different medical and health applications in the future.

We believe that the best use of any additional funding would be to pursue clinical studies and medical research to support differentiated and advantaged marketing claims, to build and enhance our competitive insulation via strategically based additional intellectual property, to develop product improvements and new products in consumer preferred dosage forms, to enhance overall marketing, to establish a scientific foundation for therapeutic applications for our technology, and to pursue best in class personnel.

Three Months Ended September 30, 2013 compared to Three Months Ended September 30, 2012

For the three months ended September 30, 2013, the Company generated gross revenues of $1,019,952 ($917,574 net of rebates) compared to gross and net revenues of $365,934 ($NIL rebates) for the three months ended September 30, 2012.  The Company sold 25,495 cans (300 grams/can) of its product during the three months ended September 30, 2013 compared to sales of 8,927 cans (300 grams/can) of its product during the three months ended September 30, 2012.  Gross profit for the three months ended September 30, 2013 was $490,143 compared to $11,344 for the three months ended September 30, 2012.  General and administrative expenses for the three months ended September 30, 2013 was $1,271,562 compared to $1,058,968 for the three months ended September 30, 2012, mostly due to higher advertising costs.  Other income for the three months ended September 30, 2013 was income of $837 compared to income of $235,046 for the three months ended September 30, 2012, mostly due to no income recorded from the change in the fair value of our outstanding warrants during the current period.  The net loss for the three months ended September 30, 2013 was $780,582 compared to a net loss of $812,578 for the three months ended September 30, 2012.

22

Research and development costs (which are included in general and administrative expenses) for the three months ended September 30, 2013 was $112,924 compared to $18,279 for the three months ended September 30, 2012.

Upon completion of our quarterly impairment testing for indefinite lived intangible assets after the third quarter of 2013, we determined that the carrying values of the intellectual property intangible assets did not exceed its fair value. As a result, no impairment existed and there was no change to the carrying amount of intellectual property for the three months ended September 30, 2013.

Nine Months Ended September 30, 2013 compared to Nine Months Ended September 30, 2012

For the nine months ended September 30, 2013, the Company generated gross revenues of $2,140,595 ($1,910,287 net of rebates) compared to gross and net revenues of $734,363 ($NIL rebates) for the nine months ended September 30, 2012.  The Company sold 53,517 cans (300 grams/can) of its product during the nine months ended September 30, 2013 compared to sales of 17,285 cans (300 grams/can) of its product during the nine months ended September 30, 2012.  Gross profit for the nine months ended September 30, 2013 was $1,038,099 compared to $78,366 for the nine months ended September 30, 2012.  General and administrative expenses for the nine months ended September 30, 2013 was $3,896,374 compared to $2,091,975 for the nine months ended September 30, 2012, mostly due to higher advertising, salary and consulting costs.   Other income (expense) for the nine months ended September 30, 2013 was income of $3,959 compared to expense of ($882,667) for the nine months ended September 30, 2012, mostly due to no interest expense during the current period.  The net loss for the nine months ended September 30, 2013 was $2,854,316 compared to a net loss of $2,896,286 for the nine months ended September 30, 2012.

Research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 was $398,199 compared to $18,279 for the nine months ended September 30, 2012.

Period from April 11, 2007 (Date of Inception) to September 30, 2013

In the period from April 11, 2007 (inception) to September 30, 2013, we generated gross revenues $3,184,141 ($2,921,489 net of rebates, including net revenues from MHP of $2,743,759) while incurring $11,772,539 in general and administrative expenses. The cumulative net loss since inception is $12,500,022 including net non-cash derivatives valuation adjustments of $1,680,267 and intellectual property impairment charges of $2,662,000. 

The Company incurred research and development costs (which are included in general and administrative expenses) in the period from April 11, 2007 (inception) to September 30, 2013 of $605,020.

Upon completion of our annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011, we determined that the carrying values of the intellectual property intangible assets exceeded its fair value and we recorded noncash impairment charges totaling $2,662,000, reducing the carrying value of the asset to its fair value of $2,000,000. Such revaluation did not affect our cash flow.

Liquidity and Capital Resources

The Company plans to incur approximately $687,000 in research and development costs within the next two fiscal quarters in addition to its normal operating cash needs.

As of September 30, 2013, we had cash of $1,883,464 and $4,708,989 in total assets (which includes $2,038,117 of intangible assets).  For the nine months ended September 30, 2013, we used cash of $2,096,198.  We also have funds up to $500,000 available in a line of credit (See NOTE 10 - Commitments, Contingencies and other Comments).  Additionally, the Company may seek to raise additional capital through the issuance of debt or equity securities.  We believe we will have sufficient funds for operations, inventory procurement, product development and research and development costs through September 30, 2014.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.

Critical Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes, and disclosure of contingent liabilities at the date of the financial statements. Estimates are used for, but not limited to, the selection of the useful lives of property and equipment, provisions necessary for contingent liabilities, fair values, revenue recognition, taxes, budgeted costs and other similar charges. Management believes that the estimates utilized in preparing its financial statements are reasonable and prudent. Actual results could differ from these estimates.

23

Impact of Derivative Accounting

As a result of recent financing transactions we have entered into, our financial statements are impacted by the accounting effect of the application of derivative accounting. ASC Topic 815 and ASC Topic 815-40 govern the accounting treatment for both freestanding and embedded derivative financial instruments in our financial statements. Generally, warrants, conversion features in debt, and similar terms that include “full-ratchet” or reset provisions, which mean that the exercise or conversion price adjusts to pricing in subsequent sales or issuances, no longer meet the definition of indexed to a company's own stock and are not an exemption for equity classification provided in ASC Topic 815-15. The amount of non-cash gains or losses we record is based upon the fair market value of our common stock on the measurement date. The fair value of certain warrants outstanding which have “full-ratchet” or reset provisions (whereby the exercise or conversion price adjusts to pricing in subsequent sales or issuances in certain instances) is based on judgment as to the expected future volatility of our common stock.

Long-lived Assets

We apply the provisions of Financial Accounting Standard Board (FASB) Accounting Standards Codification (ASC) No. 360, Property, Plant and Equipment. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets.  Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

We test long-lived assets, including property, plant and equipment and other assets, for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value.  Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets.  We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset.  If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value.  The estimation of fair value is generally measured by discounting expected future cash flows as the rate we utilize to evaluate potential investments.  We estimate fair value based on the information available in making the necessary estimates, judgments and projections.

Fair Value of Indefinite-Lived Intangible Assets

Our policy is to evaluate indefinite-lived intangible assets for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An intangible asset with an indefinite life (the intellectual property) is evaluated for possible impairment by comparing the fair value of the asset with its carrying value. Fair value is estimated as the discounted value of future revenues arising from a trademark using a royalty rate that an independent party would pay for use of that trademark. An impairment charge is recorded if the trademark's carrying value exceeds its estimated fair value. An impairment charge is recorded if the carrying value of the goodwill exceeds its implied fair value. See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

Equity Based Compensation

We account for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures.

We use the Black-Scholes option-pricing model as our method of valuation for share-based compensation. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

Income Taxes

We account for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years.  Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before we are able to realize their benefits, or that future deductibility is uncertain.

24

We record a valuation allowance for deferred tax assets, if any, based on our estimates of future taxable income as well as tax planning strategies when it is more likely than not that a portion or all of its deferred tax assets will not be realized.  If we are able to utilize more of our deferred tax assets than the net amount previously recorded when unanticipated events occur, an adjustment to deferred tax assets would increase our net income when those events occur.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 We are a smaller reporting company and therefore, we are not required to provide information required by this Item of Form 10-Q.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that is designed to ensure that information we are required to disclose in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.  Disclosure controls and procedure include, without limitations, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed by our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013.  Based on that evaluation, these officers concluded that our disclosure controls and procedures were effective in providing reasonable assurance that the information required to be disclosed in our reports filed or submitted under the Exchange Act for the quarter ended September 30, 2013 was recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II-OTHER INFORMATION

Item 1.  Legal  Proceedings.

None.

Item1A.  Risk Factors.

Factors that could cause our actual results to differ materially from those in this report are any of the risks described in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.  Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition.  Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

As of the date of this report, except as set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

None

25

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information.

None

Item 6.  Exhibits.

No.	Description
31.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act 0f 2002
32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act 0f 2002
101.CAL *	XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH *	XBRL Taxonomy Extension Schema Document
101.DEF *	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *	XBRL Taxonomy Extension Labels Linkbase Document
101.PRE *	XBRL Taxonomy Extension Presentation Linkbase Document

* XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MYOS CORPORATION
Date:  November 8, 2013	By:	/s/ Carl DeFreitas
		Name: Carl DeFreitas
		Title: Chief Financial Officer

27

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I,   Peter Levy, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of MYOS Corporation (the “report”);

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:   November  8, 2013

By:	/s/ Peter Levy
Name:	Peter Levy
Title:	President and Chief Operating Officer
	(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I,   Carl J. DeFreitas, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of MYOS Corporation (the “report”);

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 8, 2013

By:	/s/ Carl J. DeFreitas
Name:	Carl J. DeFreitas
Title:	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of MYOS Corporation (the “Company”) for the quarter ended September 30, 2013, (the “Report”), I, Peter Levy, the Principal Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  November 8, 2013

By:	/s/ Peter Levy
Name:	Peter Levy
Title:	President and Chief Operating Officer
	(Principal Executive Officer)

This certification accompanies this report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purpose of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of MYOS Corporation (the “Company”) for the quarter ended September 30, 2013, (the “Report”), I, Carl J. DeFreitas, the Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  November 8, 2013

By:	/s/ Carl J. DeFreitas
Name:	Carl J. DeFreitas
Title:	Chief Financial Officer
	(Principal Financial Officer)

This certification accompanies this report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purpose of Section 18 of the Securities Exchange Act of 1934, as amended.

XML

Income Taxes

9 Months Ended

Sep. 30, 2013

Income Taxes [Abstract]

INCOME TAXES

NOTE 9 - INCOME TAXES

Income tax expense for the nine months ended September 30, 2013 and 2012 is shown as follows:

Nine months ended September 30,	2013		2012
Current	$	1,300	$	1,550
Deferred		-		-
Total	$	1,300	$	1,550

The effects of temporary differences between the financial reporting and income tax bases of assets and liabilities which give rise to the deferred tax assets and liabilities are presented below:

	September 30,  2013			December 31, 2012
Deferred tax assets:
Goodwill	$	588,015		$	672,348
Net operating losses		3,104,230			2,133,004
Other		1,582			1,542
Total deferred tax assets		3,693,827			2,806,894
Valuation allowance		(3,681,438	)		(2,804,632	)
Total net deferred tax assets		12,389			2,262
Deferred tax liabilities:
Depreciation		(12,389	)		(2,262	)
Total deferred tax liabilities		(12,389	)		(2,262	)
Net deferred tax asset	$	-		$	-

The valuation allowance for the deferred tax asset increased by $876,806 for the nine months ended September 30, 2013.

The Company has net operating losses amounting to approximately $7,891,134 that expire in various periods through 2033.  The ultimate realization of the net operating losses is dependent upon future taxable income, if any, of the Company and may be limited in any one period by alternative minimum tax rules.  Although management believes that the Company will have sufficient future taxable income to absorb the net operating loss carryovers before the expiration of the carryover period, the current global economic crisis imposes additional profitability risks that are beyond the Company’s control.  Accordingly, management has determined that a full valuation allowance of the deferred tax asset is appropriate at this time.

Internal Revenue Code Section 382 imposes limitations on the use of net operating loss carryovers when the stock ownership of one or more 5% shareholders (shareholders owning 5% or more of the Company’s outstanding capital stock) has increased by more than 50 percentage points.  Management intends to carefully monitor share ownership of 5% shareholders but cannot control the ownership changes occurring as a result of public trading of the Company’s Common Stock.  Accordingly, there is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover.

The Company has no uncertain income tax positions.

The tax years ended December 31, 2007 through 2012 are open for examination by federal and state taxing authorities.

The statutory federal income tax rate and the effective rate are reconciled as follows:

	September 30, 2013			September 30, 2012
Statutory federal income tax rate		34.00	%		34.00	%
State taxes, net of federal tax benefit		5.94	%		5.00	%
Valuation allowance		(39.94	)%		(39.00	)%
Net deferred tax asset		-	%		-	%

XML

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		78 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Statements of Operations [Abstract]
Revenue	$ 917,574	$ 365,934	$ 1,910,287	$ 734,363	$ 2,921,489
Cost of sales	427,431	354,590	872,188	655,997	1,785,154
Gross profit	490,143	11,344	1,038,099	78,366	1,136,335
General and administrative expenses	1,271,562	1,058,968	3,896,374	2,091,975	11,772,539
Loss from operations	(781,419)	(1,047,624)	(2,858,275)	(2,013,609)	(10,636,204)
OTHER INCOME (EXPENSE)
Interest income	847	5,561	3,969	5,561	12,445
Interest expense	(10)	(106)	(10)	(802,614)	(827,030)
Value of warrants in excess of the amount of additional paid-in capital received in the related private placement of restricted common stock					(2,405,303)
Change in fair value of warrants		229,591		(16,173)	4,085,570
Impairment charge - intellectual property					(2,662,000)
Amortization of deferred financing costs				(69,451)	(80,000)
Gain on forgiveness of debt					12,500
Total other income (expense)	837	235,046	3,959	(882,677)	(1,863,818)
Net loss	$ (780,582)	$ (812,578)	$ (2,854,316)	$ (2,896,286)	$ (12,500,022)
Weighted average number of common shares outstanding, basic and diluted	110,907,236	106,387,551	110,597,267	86,017,222
Basic and diluted net loss per share attributable to common stockholders	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)

XML

Private Placements of Restricted Common Stock

9 Months Ended

Sep. 30, 2013

Private Placements of Restricted Common Stock [Abstract]

PRIVATE PLACEMENTS OF RESTRICTED COMMON STOCK

NOTE 2 - PRIVATE PLACEMENTS OF RESTRICTED COMMON STOCK

During April 2007, the Company sold 28,000,000 (after adjusting for the 1 to 14 split) shares of its common stock to its founders for cash proceeds of $5,000.  During December 2007, the Company sold 21,000,000 (after adjusting for the 1 to 14 split) shares of its common stock in a private placement for cash proceeds of $75,000.

From February 25 through July 12, 2011, the Company issued an aggregate of 8,134,997 shares of common stock and warrants to purchase 8,134,997 shares of common stock to certain accredited investors (the “Private Placements”) with piggy-back registration rights.  Each warrant had a three-year term and was exercisable at $0.10 per share (due to the triggering of a down round full ratchet anti dilution provision).  In June and September 2012, 8,018,330 of warrants were exchanged for 1,603,673 shares of the Company's common stock and 116,667 warrants were exercised for $11,667.

On December 2, 2011, one accredited investor purchased 200,000 shares for gross proceeds of $40,000 in a private placement.  The subscription agreement contained a "Purchase Price Protection" provision that granted the investor additional shares in the event of a private placement during the ten month period from the date of the investment at a price per share less than the investor's purchase price.  The additional shares were to be issued for no additional payment such that the total per share price paid by this investor will equal the amount paid by investors in such later private placement.  In April 2012, the Company issued an additional 200,000 shares to the investor as a result of the price protection provision.

During February and March 2012, the Company issued an aggregate of 10,250,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $1,025,000.  The securities are subject to piggyback registration rights.

In April 2012, the Company issued an aggregate of 1,000,000 shares of restricted common stock to one accredited investor in a private placement and received aggregate gross proceeds of $100,000.  The securities are subject to piggyback registration rights.

In June 2012, the Company issued an aggregate of 2,400,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $600,000.  The securities are subject to registration rights.

In July 2012, the Company issued an aggregate of 20,580,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of $5,144,990.  The securities are subject to registration rights.

The Company received aggregate gross proceeds of $9,350,490 from the private placements as follows:

Date	Shares		Gross Proceeds		Related Warrant Liability at Inception		Related Warrant Liability at September 30, 2013
February 25, 2011		4,766,666	$	1,430,000	$	2,350,251	$	-
May 31, 2011		1,409,999		423,000		1,186,859		-
June 27, 2011		1,874,999		562,500		1,243,838		-
July 12, 2011		83,333		25,000		57,742		-
December 2, 2011		200,000		40,000		-		-
February 10, 2012		3,250,000		325,000		-		-
February 14, 2012		4,000,000		400,000		-		-
March 7, 2012		1,000,000		100,000		-		-
March 15, 2012		1,750,000		175,000		-		-
March 22, 2012		250,000		25,000		-		-
April 9, 2012		1,000,000		100,000		-		-
April 24, 2012		* 200,000		-		-		-
June 28, 2012		2,400,000		600,000		-		-
July 6, 2012		20,580,000		5,144,990		-		-
		42,764,997	$	9,350,490	$	4,838,690	$	-

* Shares issued under price protection provision of subscription agreement as described above.

The warrants were subject to full ratchet anti-dilution protection if the Company sold shares or share-indexed financing instruments at less than the $0.60 exercise price.  Repricing events occurred twice while the warrants were issued, once to $0.20 on December 2, 2011 and again to $0.10 on February 10, 2012 as a result of private placements of restricted common stock.  The warrants issued in this financing arrangement did not meet the conditions for equity classification and were required to be carried as a derivative liability, at fair value.  Management estimated the fair value of the warrants on the inception dates, and subsequently at each reporting period, using the Black-Scholes option-pricing model, adjusted for dilution, because that technique embodies all of the assumptions (including volatility, expected terms, dilution and risk free rates) that are necessary to determine the fair value of freestanding warrants.

On June 27, 2012, holders of an aggregate of 7,529,999 warrants exchanged those warrants for 1,506,004 shares of common stock.

On September 24, 2012, holders of an aggregate of 488,331 warrants exchanged those warrants for 97,669 shares of common stock.

On September 24, 2012, a holder of 116,667 warrants exercised those warrants at $0.10 a share and received 116,667 shares of common stock.

XML

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2013

Income Taxes [Abstract]

Summary of income tax expense

Nine months ended September 30,	2013		2012
Current	$	1,300	$	1,550
Deferred		-		-
Total	$	1,300	$	1,550

Deferred tax assets and liabilities

	September 30,  2013			December 31, 2012
Deferred tax assets:
Goodwill	$	588,015		$	672,348
Net operating losses		3,104,230			2,133,004
Other		1,582			1,542
Total deferred tax assets		3,693,827			2,806,894
Valuation allowance		(3,681,438	)		(2,804,632	)
Total net deferred tax assets		12,389			2,262
Deferred tax liabilities:
Depreciation		(12,389	)		(2,262	)
Total deferred tax liabilities		(12,389	)		(2,262	)
Net deferred tax asset	$	-		$	-

Statutory federal income tax rate and the effective rate reconciliation

	September 30, 2013			September 30, 2012
Statutory federal income tax rate		34.00	%		34.00	%
State taxes, net of federal tax benefit		5.94	%		5.00	%
Valuation allowance		(39.94	)%		(39.00	)%
Net deferred tax asset		-	%		-	%

XML

Commitments, Contingencies and Other Comments

9 Months Ended

Sep. 30, 2013

Commitments, Contingencies and Other Comments [Abstract]

COMMITMENTS, CONTINGENCIES AND OTHER COMMENTS

NOTE 10 - COMMITMENTS, CONTINGENCIES AND OTHER COMMENTS

Distribution Agreement

On May 16, 2012, the Company entered into a distribution agreement (the "Agreement") with MHP, a company engaged in the development, marketing and distribution of nutritional and other therapies for the consumer.  Pursuant to the Agreement, MHP will, on an exclusive basis, provide marketing, sales and distribution of MYO-T12, to be sold under the brand name MYO-X, in retail and other outlets.  MHP agreed to pay the Company $195,301 upon the execution of the Agreement, with such amount credited against inventory purchases.  The Agreement also provides, upon termination of MHP's exclusivity rights, additional supply and payment rights to MHP (including a per-unit royalty in the low single digits).  The Agreement provided for one year of exclusivity for MHP, which expired on September 29, 2013.  While the Agreement remains in effect, the parties are currently negotiating a new agreement.  The Agreement further provides for a co-operative advertising arrangement with MHP, whereby the Company is required to pay MHP a fee for each unit of MYO-X sold, and rebate payments to MHP based on a percentage of product cost reductions realized by the Company.

Bank Line of Credit

In October 2013, the Company was granted a $500,000 line of credit by City National Bank, that bears a per annum interest rate through April 15, 2014 equal to the prime rate, after which the rate changes to the prime rate plus 1.25 percent.  As of the date of this report, the Company has not drawn on the line of credit.

Operating Lease

The Company leases its corporate offices under an operating lease expiring in July 2017.  The Company has two options to renew such lease for a term of three years each with annual rent increases of 3%.

The future minimum lease payments under the non-cancellable operating lease in excess of one year at September 30, 2013 is as follows:

Year Ending December 31,	Amount
2013	$	14,042
2014		59,434
2015		65,095
2016		67,163
2017		39,623
Total	$	245,357

Rent expense for the nine months ended September 30, 2013 and 2012 was $44,018 and $22,155, respectively.

Supply Agreement

On June 24, 2013, the Company entered into a supply agreement with Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”).  The agreement obligates the Company to minimum annual quantity purchases, and provides that DIL will manufacture and supply the Company with the proprietary product contained in MYO-X and that DIL shall only manufacture the product for commercial purposes with the Company’s consent.  The term of the agreement is for two years, and will continue indefinitely until terminated by either party upon three months written notice.

Employment Agreements

J.B. Bernstein:

On February 25, 2011, the Company entered into an employment agreement with J.B. Bernstein, pursuant to which Mr. Bernstein served as Chief Executive Officer of the Company.  The employment agreement was amended effective as of March 1, 2011.  On April 30, 2012, J.B. Bernstein resigned from his positions as President and Chief Executive Officer and as a member of the Company’s board of directors.  In connection with his resignation, Mr. Bernstein entered into a consulting agreement with the Company (the “Consulting Agreement”), pursuant to which Mr. Bernstein was entitled to a consulting fee of $5,000 per month during the six-month term of the Consulting Agreement, which expired on October 31, 2012.  The Consulting Agreement also included confidentiality and non-competition obligations and provisions for intellectual property assignments by Mr. Bernstein.

Carlon Colker MD, FACN:

On February 25, 2011, concurrent with the closing of the Acquisition, the Company entered into an employment agreement with Carlon Colker, MD, FACN, pursuant to which Dr. Colker agreed to serve as Chief Medical Officer and Executive Vice President of the Company.  On June 14, 2012, Dr. Carlon Colker resigned from his positions as Chief Medical Officer and Executive Vice President.  Simultaneously with his resignation, Dr. Colker agreed to serve on the Company’s Scientific Advisory Board.  In connection with his appointment to the Scientific Advisory Board, Dr. Colker entered into an advisory board agreement with the Company, pursuant to which the Company issued him 300,000 shares of common stock.  The Agreement also includes standard confidentiality and non-competition obligations and provisions for intellectual property assignments by Dr. Colker.

Glen R. Fleischer:

On January 2, 2013, we entered into an employment agreement with Glen R. Fleischer pursuant to which Mr. Fleischer agreed to serve as our Chief Executive Officer and as a member of our board of directors.

Pursuant to the terms of the agreement, Mr. Fleischer would work for us on a full-time basis and receive an annual base salary of $320,000.  Mr. Fleischer was also entitled to an annual cash bonus in an amount up to 100% of his base salary, as determined by our board of directors in its sole discretion. In addition, Mr. Fleischer was granted 5,000,000 shares of our common stock, which shares were to vest in four equal semi-annual installments commencing on July 2, 2013. The term of the agreement was three years, and the agreement was to automatically renew for successive one-year periods, unless a notice of non-renewal was provided by either party at least sixty days prior to the expiration date of the term.  On April 25, 2013, Mr. Fleischer resigned as our Chief Executive Officer and as a member of our board of directors.

Peter A. Levy:

On February 8, 2013, we entered into an amended and restated employment agreement with Peter Levy to continue to serve as our Chief Operating Officer and Executive Vice President. The agreement replaced Mr. Levy’s existing employment agreement dated February 10, 2012.  Pursuant to the terms of the agreement, Mr. Levy will continue to work as Chief Operating Officer and Executive Vice President on a full-time basis and receive an annual base salary of $200,000.    Mr. Levy may receive an annual cash bonus in an amount up to 100% of his base salary, as may be determined by the Board in its sole discretion. The 500,000 shares of common stock previously granted to Mr. Levy will vest in four equal semi-annual installments commencing on August 10, 2012. The term of the agreement is three years, and the agreement will automatically renew for successive one-year periods, unless a notice of non-renewal is provided by either party at least sixty days prior to the expiration date of the term.  

In the event Mr. Levy’s employment is terminated for cause (as defined in the agreement) or as a result of death or disability, or if Mr. Levy terminates his employment without good reason (as defined in the agreement), Mr. Levy will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as retain any shares that have previously vested.

In the event Mr. Levy’s employment is terminated for any reason other than cause, death or disability, or if Mr. Levy terminates his employment for good reason, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as any vested shares. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination.

In the event Mr. Levy’s employment is terminated in connection with, or as a result of, a change of control (as defined in the agreement), or if Mr. Levy terminates his employment for good reason following a change in control, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination. Furthermore, all of his unvested shares will vest as of the date of the consummation of the change in control.

The agreement contains customary non-competition and non-solicitation provisions that extend to two years after termination of Mr. Levy’s employment.  Mr. Levy also agreed to customary terms regarding confidentiality and ownership of product ideas.

On April 21, 2013, Mr. Levy was appointed to the additional position of President of the Company and in such capacity will serve as the Company's Principal Executive Officer.

Sponsorship Agreement

On June 27, 2011, the Company entered into a one year agreement with a celebrity spokesperson pursuant to which the spokesperson agreed to perform certain services for the Company and granted the Company the worldwide right to use the spokesperson’s name and approved image in various media.  The agreement provided for cash compensation of $150,000 in three equal installments of $50,000, all of which was paid in 2011.  Royalties at the rate of $0.50 per unit sold are payable to the spokesperson for the term of the agreement and an additional 12 months thereafter.  The agreement expired in June 2012.

The agreement also provided for the issuance of warrants to purchase 150,000 shares of common stock, 100,000 of which were issued upon signing of the agreement and 50,000 of which were issued in December 2011.  The warrants have a term of two years with an exercise price of $1.00 per share.  The warrants further provide that in the event (a) the trading price of the common stock of the Company on its principal trading market does not exceed $2.00 within two years of issuance and (b) the warrants are not exercised prior to such time, then the spokesperson shall have the right to sell any unexercised portion of the warrants to the Company in exchange for $1.00 for each share of common stock underlying the unexercised portion of the warrants.

The 100,000 warrants issued upon execution of the agreement and the 50,000 warrants issued in December 2011 were valued at September 30, 2013 at $NIL and $43,950, respectively, using a Black-Scholes option pricing model with the put option as the predominant feature of the instrument.  On June 27, 2013, the 100,000 warrants expired and a $100,000 liability was recorded.

Director Agreements

Dr. Louis Aronne:

On July 14, 2011, the Company entered into two separate agreements with Dr. Louis Aronne to be a member of the Board of Directors and the Scientific Advisory Board.  The director agreement provides for compensation in the form of 100,000 shares of restricted common stock vesting in five equal annual installments commencing on execution of the agreement and an option to purchase 250,000 shares of common stock at an exercise price of $0.64 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option will vest immediately.  The advisory board agreement has a term of 5 years and provides for the issuance of 500,000 shares vesting in five equal annual installments commencing July 14, 2012 and an option to purchase 500,000 shares at $.64 per share vesting in four equal annual installments, and the first installment vested immediately upon the execution of the agreement.  Upon a Change of Control, all unvested option shall immediately vest.

Dr. Robert Hariri:

On July 26, 2011, the Company entered into an agreement with Dr. Robert Hariri to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.69 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option shall immediately vest. 

Dr. Peter Diamandis:

On August 15, 2011, the Company entered into an agreement with Dr. Peter Diamandis to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.45 for 10 years vesting over a period of 3 years,  the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Buzz Aldrin:

On May 24, 2012, the Company entered into an agreement with Dr. Buzz Aldrin to be a member of the Board of Directors.  The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of $0.14 for 10 years vesting over a period of 3 years, the first installment of which vested immediately.  Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Sapna Srivastava:

On February 6, 2013, the Company entered into an agreement with Dr. Sapna Srivastava to serve as a member of the Board of Directors.  The director agreement provides for the issuance of 100,000 shares of restricted common stock, vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock, issued under the Plan, at an exercise price of $0.20 for 10 years vesting over a period of 3 years. The options are subject to the terms and provision of the Plan.

XML

Income Taxes (Details 2)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statutory federal income tax rate and the effective rate reconciliation
Statutory federal income tax rate	34.00%	34.00%
State taxes, net of federal tax benefit	5.94%	5.00%
Valuation allowance	(39.94%)	(39.00%)
Net deferred tax asset

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 5) (USD $)	4 Months Ended	6 Months Ended	9 Months Ended
	Jul. 12, 2011	Jul. 12, 2011	Sep. 30, 2013
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			9,541,000
Expected Term	3 years	3 years
07/14/11 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			750,000
Stock Price on Measurement Date			$ 0.64
Exercise Price			$ 0.64
Expected Term			10 years
Expected Volatility			287.00%
Dividend Yield			0.00%
Risk Free Rate			2.98%
07/26/11 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			250,000
Stock Price on Measurement Date			$ 0.69
Exercise Price			$ 0.69
Expected Term			10 years
Expected Volatility			285.00%
Dividend Yield			0.00%
Risk Free Rate			2.99%
08/15/11 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			250,000
Stock Price on Measurement Date			$ 0.45
Exercise Price			$ 0.45
Expected Term			10 years
Expected Volatility			284.00%
Dividend Yield			0.00%
Risk Free Rate			2.29%
05/24/12 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			250,000
Stock Price on Measurement Date			$ 0.14
Exercise Price			$ 0.14
Expected Term			10 years
Expected Volatility			187.00%
Dividend Yield			0.00%
Risk Free Rate			1.77%

XML

Nature of Organization and Significant Accounting Policies (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of Fixed assets
Total fixed assets	$ 354,959	$ 9,838
Less accumulated depreciation	(27,000)	(1,449)
Net book value of fixed assets	327,959	8,389
Furniture and fixtures [Member]
Summary of Fixed assets
Total fixed assets	100,758	3,024
Computers and software [Member]
Summary of Fixed assets
Total fixed assets	15,247	6,814
Leasehold improvements [Member]
Summary of Fixed assets
Total fixed assets	233,954
Other [Member]
Summary of Fixed assets
Total fixed assets	$ 5,000

XML

Nature of Organization and Significant Accounting Policies (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of Inventory
Raw materials	$ 10,869	$ 213,848
Work in process
Finished goods		4,469
Total Inventory	$ 10,869	$ 218,317

XML

Income Taxes (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Summary of income tax expense
Current	$ 1,300	$ 1,550
Deferred
Total	$ 1,300	$ 1,550

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 1) (USD $)	1 Months Ended		9 Months Ended		12 Months Ended
	Sep. 24, 2012	Jun. 27, 2012	Sep. 30, 2013	Sep. 30, 2013 Warrant [Member]	Dec. 31, 2012 Warrant [Member]	Dec. 31, 2011 Warrant [Member]	Dec. 31, 2011 Warrant [Member] Original [Member]	Dec. 31, 2011 Warrant [Member] Repriced [Member]
Summary of activity in warrants
Beginning Balance, Shares Under Options/Warrants				150,000	8,284,997
Number of Options/Warrants			9,541,000			8,284,997
Options/Warrants exercised, Share Under Options/Warrants					(116,667)
Options/Warrants cancelled/expired, Shares Under Options/Warrants	488,331	7,529,999		100,000	(8,018,330)
Balance, Shares Under Options/Warrants				50,000	150,000	8,284,997
Beginning Balance, Weighted Average Exercise Price				$ 1.00			$ 0.61	$ 0.10
Warrants/Options granted, Weighted Average Exercise Price				$ 1.00
Balance, Weighted Average Exercise Price				$ 1.00	$ 1.00		$ 0.61	$ 0.10

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 7) (USD $)	9 Months Ended
	Sep. 30, 2013
Summary of stock options issued to stockholders
Number of Options/Warrants	9,541,000
Expiration term	10 years
2012 Equity Incentive Plan [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	9,541,000
2012 Equity Incentive Plan [Member] | Employee [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	112,000
Expiration term	10 years
2012 Equity Incentive Plan [Member] | Employee [Member] | Minimum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.20
2012 Equity Incentive Plan [Member] | Employee [Member] | Maximum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.25
2012 Equity Incentive Plan [Member] | Consultants [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	1,327,000
Expiration term	10 years
2012 Equity Incentive Plan [Member] | Consultants [Member] | Minimum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.20
2012 Equity Incentive Plan [Member] | Consultants [Member] | Maximum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.25
2012 Equity Incentive Plan [Member] | Officers [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	1,152,000
Expiration term	10 years
2012 Equity Incentive Plan [Member] | Officers [Member] | Minimum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.20
2012 Equity Incentive Plan [Member] | Officers [Member] | Maximum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.25
2012 Equity Incentive Plan [Member] | Directors [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	6,700,000
Expiration term	10 years
2012 Equity Incentive Plan [Member] | Directors [Member] | Minimum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.14
2012 Equity Incentive Plan [Member] | Directors [Member] | Maximum [Member]
Summary of stock options issued to stockholders
Exercise Price	$ 0.35
2012 Equity Incentive Plan [Member] | Scientific Advisory Board [Member]
Summary of stock options issued to stockholders
Number of Options/Warrants	250,000
Exercise Price	$ 0.25
Expiration term	10 years

XML

Income Taxes (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013
Income Taxes (Textual)
Increase in valuation allowance of deferred tax assets	$ 876,806
Operating loss carryforward	$ 7,891,134
Expiration period of operating loss carryforward	Expire in various periods through 2033
Condition for limitation on use of operating loss carryovers	One or more 5% shareholders (shareholders owning 5% or more of the Company's outstanding capital stock) has increased by more than 50 percentage points
Percentage of outstanding capital stock owned by shareholders	5.00%
Increment in shareholders ownership	More than 50
Percentage point increase in stock ownership	50.00%

XML

Notes and Loans Payable (Details) (USD $)	0 Months Ended	1 Months Ended	9 Months Ended		12 Months Ended		78 Months Ended				0 Months Ended	1 Months Ended	9 Months Ended					9 Months Ended		1 Months Ended		9 Months Ended
	Sep. 20, 2012	Nov. 30, 2011	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Jun. 28, 2012	Nov. 29, 2011	May 20, 2010	Sep. 29, 2011 Director [Member]	Jun. 28, 2012 Director [Member]	Sep. 30, 2012 Director [Member]	Jan. 31, 2012 Director [Member]	Dec. 31, 2011 Director [Member]	Nov. 29, 2011 Director [Member]	Oct. 31, 2011 Director [Member]	Sep. 30, 2012 Chief Executive Officer [Member]	Jul. 15, 2012 Chief Executive Officer [Member]	Jun. 28, 2012 Convertible Notes Payable [Member]	Nov. 30, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 Convertible Notes Payable [Member]	Nov. 29, 2011 Convertible Notes Payable [Member]
Notes and Loans Payable (Textual)
Convertible notes payable								$ 400,000	$ 400,000							$ 150,000
Notes payable bearing interest										5.00%	3.00%												18.00%
Notes payable due date											Oct. 29, 2011										May 29, 2013
Conversion price of notes convertible into common stock												$ 0.20								$ 0.20			$ 0.20
Advance to company											60,000
Advance direct payment to a vendor														19,500	10,000		10,000
Loans payable											99,500								65,000
Accrued interest of notes payable																				41,800
Notes payable amount converted on to common stock shares	30,000											507,306								2,209,000
Principal, accrued interest on loans and advances of notes payable												142,046								618,520
Loan and advances aggregate amount												101,461
Advances of notes payable												1,961
Interest expense													143,557					188				654,123
Shares issued in connection with debt, (Shares)		400,000
Shares issued in connection with debt		60,000			1,346,139	60,000
Price per share									$ 0.15
Related amortization expense			34,000
Term at which shares amortized			Over the six month term of the notes.
Amortization				49,451			80,000
Note payable										7,500
Repayment of accounts receivable										$ 7,500

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 10)	9 Months Ended
	Sep. 30, 2013
$ 0.14 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.14
Options outstanding	150,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 6 months 4 days
Options exercisable, Range of Exercise Price	0.14
Options Exercisable, Options Exercisable
$ 0.19 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.19
Options outstanding	150,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 9 months 4 days
Options exercisable, Range of Exercise Price	0.19
Options Exercisable, Options Exercisable
$ 0.20 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.20
Options outstanding	606,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 3 months 22 days
Options exercisable, Range of Exercise Price	0.20
Options Exercisable, Options Exercisable	159,333
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 3 months 26 days
$ 0.22 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.22
Options outstanding	150,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 3 months 11 days
Options exercisable, Range of Exercise Price	0.22
Options Exercisable, Options Exercisable
$ 0.25 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.25
Options outstanding	3,485,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 4 months 24 days
Options exercisable, Range of Exercise Price	0.25
Options Exercisable, Options Exercisable	358,332
$ 0.35 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.35
Options outstanding	5,000,000
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 4 months 10 days
Options exercisable, Range of Exercise Price	0.35
Options Exercisable, Options Exercisable
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 3 months 15 days
$ 0.14 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.14
Options outstanding	250,000
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 7 months 24 days
Options exercisable, Range of Exercise Price	0.14
Options Exercisable, Options Exercisable	166,666
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 7 months 24 days

XML

Commitments, Contingencies and Other Comments (Tables)

9 Months Ended

Sep. 30, 2013

Commitments, Contingencies and Other Comments [Abstract]

Summary of Future minimum lease payments under the non-cancelable operating lease

Year Ending December 31,	Amount
2013	$	14,042
2014		59,434
2015		65,095
2016		67,163
2017		39,623
Total	$	245,357

XML

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2007	Dec. 31, 2011
Statement of Changes in Stockholders' Equity [Abstract]
Per share value of common stock issued	$ 0.0002
Per share value of common stock issued	$ 0.004
Common stock shares issued to Peak Wellness, Inc. as part of purchase price of intellectual property		7,024,000

XML

Consolidated Statements of Cash Flow (Unaudited) (Parenthetical)	9 Months Ended
	Sep. 30, 2013
Consolidated Statements of Cash Flows [Abstract]
Common stock and warrants, share issued	97,669
Warrant converted into common shares	488,331
Common stock and warrants, share issued one	1,506,004
Shares issued in exchange for warrants, (Shares) one	7,529,999

XML

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2013

Recent Accounting Pronouncements [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not believe that the adoption of any recently issued, but not yet effective, accounting standards will have a material effect on its financial position and results of operations.

XML

Nature of Organization and Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Nature of Organization and Significant Accounting Policies [Abstract]

NATURE OF ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – NATURE OF ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization & Business Activities

MYOS Corporation, formerly known as Atlas Therapeutics Corporation (the "Company") was incorporated under the laws of the State of Nevada on April 11, 2007.  On February 25, 2011, the Company entered into an agreement to purchase certain intellectual property from Peak Wellness, Inc. (the "Acquisition") (see Note 8 - Intellectual Property Purchase Agreement). Since the Acquisition, the Company’s business focus has been on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.  The Company has only realized revenues of $2,921,489 through September 30, 2013 without fully implementing its plan of operations and therefore is still considered a development stage company.

Depreciation

The cost of property and equipment is depreciated over the estimated useful life of 3 to 7 years.  Depreciation is computed using the straight-line method when assets are placed in service. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals.

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles and include the accounts of the Company and its wholly-owned subsidiary, Atlas Acquisition Corp. (formed on February 23, 2011 to facilitate the purchase of the intellectual property discussed in Note 8 - Intellectual Property Purchase Agreement).  All material intercompany balances and transactions have been eliminated.  These financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be a cash equivalent.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.

Fair Value of Indefinite-Lived Intangible Assets

The Company accounts for indefinite-lived intangible assets in accordance with ASC 350, Intangibles-Goodwill and Other.  In accordance with ASC 350, indefinite-lived intangible assets are subject to an impairment analysis at least annually, and more frequently upon the occurrence of certain events.  The impairment analysis is performed by comparing the fair value of the assets with the carrying value of the assets.  Fair value is estimated as the discounted value of future revenues arising from the use of such assets.  An impairment charge is recorded if the assets carrying value exceed the assets estimated fair value.

The Company's policy is to evaluate indefinite-lived intangible assets (e.g. the intellectual property) for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was $2,000,000.  Management performed their quarterly review of the intellectual property and determined no impairment existed and there was no change to the carrying value for the nine months ended September 30, 2013.

Revenue Recognition

The Company recognizes revenue when products are shipped and collection is reasonably assured.

Inventories

Inventory consist of the following:
	September 30,		December 31,
	2013		2012
Raw materials	$	10,869	$	213,848
Work in process		-		-
Finished goods		-		4,469
Total Inventory	$	10,869	$	218,317

Inventories are stated at the lower of cost or market, with cost determined on a first in, first-out basis.

Advertising

The Company charges the costs of advertising to expense as incurred. The Company incurred $924,368 and $260,427 of advertising and promotional costs for the nine months ended September 30, 2013 and 2012 respectively, and $1,518,930 since its inception.  Pursuant to its distribution agreement with Maximum Human Performance (“MHP”), entered into on May 16, 2012, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold (See Note 10 - Commitments, Contingencies and Other Comments - Distribution Agreement).

Fixed Assets

Fixed assets consist of the following:
	September 30, 2013			December 31, 2012
Furniture, fixtures and equipment	$	100,758		$	3,024
Computers and software		15,247			6,814
Leasehold improvements		233,954			-
Other		5,000			-
Total fixed assets		354,959			9,838
Less accumulated depreciation		(27,000	)		(1,449	)
Net book value of fixed assets	$	327,959		$	8,389

Repair and maintenance costs are expensed as incurred.  Depreciation expense was $25,553 and $771 for the nine months ended September 30, 2013 and 2012, respectively.

Concentrations of Risk, Significant Distributor and Customer and Significant Supplier

The Company maintains its bank accounts with a high credit quality financial institution and has never experienced any losses related to these bank accounts.  From December 31, 2010 through December 31, 2012, all non-interest-bearing transaction accounts were fully insured by the FDIC, regardless of the balance of the account and the ownership capacity of the funds, and interest bearing accounts were insured up to $250,000.  Beginning 2013, insurance coverage reverted back to $250,000 per depositor at each financial institution.  The Company had two noninterest-bearing checking accounts and one interest-bearing savings account which totalled $1,882,714 as of September 30, 2013.   At September 30, 2013, the Company's uninsured cash balances totalled $1,632,714.

Effective May 2012, MHP became the exclusive distributor and sole customer of the Company's MYO-X product and formula (see Note 10 - Commitments, Contingencies and Other Comments – Distribution Agreement).  MHP's exclusivity expired in September 2013.  While the distribution agreement otherwise remains in effect,  the parties are currently negotiating a new agreement.

The Company currently relies on one foreign company to produce the raw product for MYO-T12 (see Note 10 - Commitments, Contingencies and Other Comments – Supply Agreement).  The Company is considering other supply alternatives.

Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees.  ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model.  For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation.  Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables.  These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.  

Equity-based compensation expense for awards to employees and non-employees was $1,042,793 and $707,143 for the nine month periods ended September 30, 2013 and 2012, respectively.

Comprehensive Loss

The Company had no items of other comprehensive income or expense for the nine month periods ended September 30, 2013 and 2012.  Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.

Research and Development

The Company incurred $398,199 and $18,279 of research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 and 2012 respectively, and $605,020 since its inception. 

Segment Information

ASC 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information regarding operating segments in annual consolidated financial statements and requires selected information for those segments to be presented in financial reports issued to stockholders.  It also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The Company operates in a single segment, internally reports the results of operations for that segment and the information disclosed herein materially represents all of the financial information related to the single operating segment.

Fair Value Measurement

The Company adopted the provisions of ASC 820 Fair Value Measurements and Disclosures on January 1, 2009.  ASC 820 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.  Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy.  It does not require any new fair value measurements.  It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

Valuation techniques considered under ASC 820 techniques are based on observable and unobservable inputs.  The ASC classifies these inputs into the following hierarchy:

Level 1 inputs are observable inputs and use quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date and are deemed to be most reliable measure of fair value.

Level 2 inputs are observable inputs and reflect assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity.  Level 2 inputs includes 1) quoted prices for similar assets or liabilities in active markets, 2) quoted prices for identical or similar assets or liabilities in markets that are not active, 3) observable inputs such as interest rates and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, credits risks, default rates, and 4) market-corroborated inputs.

Level 3 inputs are unobservable inputs and reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

In October 2008, the FASB clarified the application of ASC 820 in determining the fair value of a financial asset when the market for that financial asset is not active.

The Company adopted the provisions of ASC 825, The Fair Value Option for Financial Assets and Liabilities, on January 1, 2009.  ASC 825 permits us to choose to measure certain financial assets and liabilities at fair value that are not currently required to be measured at fair value (the “Fair Value Option”).  Election of the Fair Value Option is made on an instrument-by-instrument basis and is irrevocable.  At the adoption date, unrealized gains and losses on financial assets and liabilities for which the Fair Value Option has been elected are reported as a cumulative adjustment to beginning retained earnings.

Our intangible assets are valued and tested for impairment using Level 3 inputs (see Note 8 - Intellectual Property Purchase Agreement).  In the process of the valuation of the intangible asset, we determined that the carrying cost exceeded the fair value at December 31, 2011 and we recorded an impairment charge and adjusted the balance of the asset to reflect the fair value.  There were no impairment charges for any subsequent periods.

Basic and Diluted Income (Loss) per Share

In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding.  Diluted loss per common share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At September 30, 2013 and 2012, the Company’s stock equivalents were anti-dilutive and excluded in the diluted loss per share computation.  The aggregate number of potentially dilutive options and warrants outstanding at September 30, 2013 and 2012 were 11,091,000 and 1,650,000, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.

The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement.  This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements.  It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions.  The Company has no uncertain income tax positions.

Interest costs and penalties related to income taxes are classified as interest expense and selling, general and administrative costs, respectively, in the Company's financial statements.  For the nine months ended September 30, 2013 and 2012, the Company did not recognize any interest or penalty expense related to income taxes.  The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business. 

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 8) (USD $)	4 Months Ended	6 Months Ended	9 Months Ended
	Jul. 12, 2011	Jul. 12, 2011	Sep. 30, 2013
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			9,541,000
Expected Term	3 years	3 years
11/20/12 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			6,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.20
Expected Term			10 years
Expected Volatility			166.00%
Dividend Yield			0.00%
Risk Free Rate			1.66%
01/01/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			150,000
Stock Price on Measurement Date			$ 0.19
Exercise Price			$ 0.22
Expected Term			10 years
Expected Volatility			164.00%
Dividend Yield			0.00%
Risk Free Rate			2.00%
01/07/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			350,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.20
Expected Term			10 years
Expected Volatility			166.00%
Dividend Yield			0.00%
Risk Free Rate			1.92%
01/07/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			2,000,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			166.00%
Dividend Yield			0.00%
Risk Free Rate			1.92%
02/07/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			5,000,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.35
Expected Term			10 years
Expected Volatility			164.00%
Dividend Yield			0.00%
Risk Free Rate			1.99%
02/07/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			450,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			164.00%
Dividend Yield			0.00%
Risk Free Rate			1.99%
02/08/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			250,000
Stock Price on Measurement Date			$ 0.19
Exercise Price			$ 0.20
Expected Term			10 years
Expected Volatility			164.00%
Dividend Yield			0.00%
Risk Free Rate			2.00%
02/28/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			100,000
Stock Price on Measurement Date			$ 0.20
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			158.00%
Dividend Yield			0.00%
Risk Free Rate			1.89%
04/01/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			150,000
Stock Price on Measurement Date			$ 0.14
Exercise Price			$ 0.14
Expected Term			10 years
Expected Volatility			160.00%
Dividend Yield			0.00%
Risk Free Rate			1.86%
05/06/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			400,000
Stock Price on Measurement Date			$ 0.12
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			161.00%
Dividend Yield			0.00%
Risk Free Rate			1.80%
05/20/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			10,000
Stock Price on Measurement Date			$ 0.12
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			161.00%
Dividend Yield			0.00%
Risk Free Rate			1.97%
05/21/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			200,000
Stock Price on Measurement Date			$ 0.12
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			161.00%
Dividend Yield			0.00%
Risk Free Rate			1.94%
05/24/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			5,000
Stock Price on Measurement Date			$ 0.13
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			160.00%
Dividend Yield			0.00%
Risk Free Rate			2.01%
06/10/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			100,000
Stock Price on Measurement Date			$ 0.16
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			160.00%
Dividend Yield			0.00%
Risk Free Rate			2.22%
07/01/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			150,000
Stock Price on Measurement Date			$ 0.19
Exercise Price			$ 0.19
Expected Term			10 years
Expected Volatility			159.00%
Dividend Yield			0.00%
Risk Free Rate			2.50%
08/21/13 [Member]
Assumption used to value directors and advisory board option using Black-Scholes option mode
Number of Options/Warrants			220,000
Stock Price on Measurement Date			$ 0.17
Exercise Price			$ 0.25
Expected Term			10 years
Expected Volatility			157.00%
Dividend Yield			0.00%
Risk Free Rate			2.87%

XML

Nature of Organization and Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		78 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Account Company	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Nature of Organization and Significant Accounting Policies (Textual)
Revenue	$ 917,574	$ 365,934	$ 1,910,287	$ 734,363	$ 2,921,489
Intellectual property	2,000,000		2,000,000		2,000,000	2,000,000
Advertising and promotional cost incurred			924,368	260,427	1,518,930
Depreciation			25,553	771	27,002
Share based compensation expenses recognized			1,042,793	707,143
Aggregate number of potentially dilutive warrants and options outstanding	11,091,000		11,091,000		11,091,000	1,650,000
Interest bearing accounts capacity of fund and balance	250,000		250,000		250,000
Interest bearing account balance	1,882,714		1,882,714		1,882,714
Uninsured cash balances	1,632,714		1,632,714		1,632,714
Amount of insurance coverage revert back per depositor	250,000		250,000		250,000
Number of noninterest-bearing checking accounts			2
Number of interest-bearing savings account			1
Number of overseas companies to produce raw product for MYO-T12			1
Research and development cost			$ 398,199	$ 18,279	$ 605,020
Minimum [Member]
Nature of Organization and Significant Accounting Policies (Textual)
Property and equipment, estimated useful life			3 years
Maximum [Member]
Nature of Organization and Significant Accounting Policies (Textual)
Property and equipment, estimated useful life			7 years

XML

Capital Stock (Details)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Feb. 12, 2010
Capital Stock (Textual)
Preferred stock, shares authorized	25,000,000	25,000,000	25,000,000
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Stock outstanding before shares stock splits			3,500,000
Stockholders' equity, stock split	14 shares for 1 basis
Increase in shares issued after forward split			49,000,000
Increase in shares outstanding after forward split			49,000,000

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 4) (USD $)	1 Months Ended		9 Months Ended		12 Months Ended
	Sep. 24, 2012	Jun. 27, 2012	Sep. 30, 2013	Sep. 30, 2013 Stock Options [Member]	Dec. 31, 2012 Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Under Options/Warrants				1,500,000	1,250,000
Warrants/Options granted, Shares Under Warrants/Options			9,541,000		250,000
Options/Warrants exercised, Share Under Options/Warrants
Options/Warrants cancelled/expired, Shares Under Options/Warrants	488,331	7,529,999
Balance, Shares Under Options/Warrants				15,000,000	1,500,000
Beginning Balance, Weighted Average Exercise Price				$ 0.53	$ 0.61
Warrants/Options granted, Weighted Average Exercise Price					$ 0.14
Balance, Weighted Average Exercise Price				$ 0.53	$ 0.53

XML

Commitments, Contingencies and Other Comments (Details) (USD $)	Sep. 30, 2013
Summary of Future minimum lease payments under the non-cancelable operating lease
2013	$ 14,042
2014	59,434
2015	65,095
2016	67,163
2017	39,623
Total	$ 245,357

XML

Intellectual Property Purchase Agreement (Details) (USD $)			1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Feb. 25, 2011 MYO-T12 [Member] Installments	Dec. 31, 2011 MYO-T12 [Member]
Intellectual Property Purchase Agreement (Textual)
Aggregate consideration paid for acquisition in cash			$ 4,662,000
Purchase price for the assets			1,150,000
Cash paid for acquisition			450,000
Issuance of promissory note			700,000
Shares issued as part of Purchase Agreement			7,024,000
Aggregate fair value of share issued as a part of the purchase price			3,512,000
Voting interest common stock, diluted			12.00%
Unpaid principal balance			700,000
Promissory Note Installments Description			Payable in two installments as follows: $350,000 plus accrued interest was due within 180 days after the closing date of the Agreement (originally August 25, 2011 but extended to the earlier of November 30, 2011 or the closing of a certain financing and paid on November 29, 2011) and $350,000 plus accrued interest was due on the first anniversary of the closing date of the Agreement and paid on February 21, 2012.
First installment, promissory note			350,000
Second installment, promissory note			350,000
Number of installments of promissory note			2
Number of days of first installment, accrued interest			180 days
Interest accruing interest rate on promissory note			3.00%
Impairment charges				2,662,000
Intellectual property asset				2,000,000
Intellectual property	$ 2,000,000	$ 2,000,000

XML

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued
Preferred stock,. shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	111,372,282	110,033,282
Common stock, shares outstanding	111,372,282	110,033,282

XML

Capital Stock

9 Months Ended

Sep. 30, 2013

Capital Stock [Abstract]

CAPITAL STOCK

NOTE 6 - CAPITAL STOCK

On February 12, 2010, the Company’s articles of incorporation were amended to increase the number of authorized preferred shares to 25,000,000 and the number of authorized common shares to 300,000,000. The Company’s 3,500,000 common shares outstanding were also forward split on a 14 shares for 1 basis with the result that 49,000,000 shares were issued and outstanding on that date. The accompanying financial statements reflect the forward stock split on a retroactive basis.

XML

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock	Additional paid-in capital	Deficit accumulated during developmental stage
Beginning Balance at Apr. 11, 2007
Beginning Balance, (Shares) at Apr. 11, 2007
Common stock issued for cash at $0.0002 per share	5,000	28,000	(23,000)
Common stock issued for cash at $0.0002 per share, (Shares)		28,000,000
Common stock issued for cash at $0.004 per share	75,000	21,000	54,000
Common stock issued for cash at $0.004 per share, (Shares)		21,000,000
Net loss	(60,185)			(60,185)
Balance at Dec. 31, 2007	19,815	49,000	31,000	(60,185)
Balance, (Shares) at Dec. 31, 2007		49,000,000
Net loss	(17,928)			(17,928)
Balance at Dec. 31, 2008	1,887	49,000	31,000	(78,113)
Balance, (Shares) at Dec. 31, 2008		49,000,000
Net loss	(39,308)			(39,308)
Balance at Dec. 31, 2009	(37,421)	49,000	31,000	(117,421)
Balance, (Shares) at Dec. 31, 2009		49,000,000
Net loss	(16,525)			(16,525)
Balance at Dec. 31, 2010	(53,946)	49,000	31,000	(133,946)
Beginning Balance, (Shares) at Dec. 31, 2010		49,000,000
Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property	3,512,000	7,024	3,504,976
Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property, (Shares)		7,024,000
Fair value of shares transferred from existing stockholder to the CEO in connection with employment agreement	1,500,000		1,500,000
Proceeds from private placements of restricted common stock	2,480,500	8,335	2,472,165
Proceeds from private placements of restricted common stock, (Shares)		8,334,997
Offering costs	(45,000)		(45,000)
Fair value of warrants issued to private placement investors	(2,432,365)		(2,432,365)
Shares issued for services	690,193	2,055	688,138
Shares issued for services, (Shares)		2,055,000
Vesting of options and shares issued to officers, directors, advisory board member, consultants and employees	360,402		360,402
Shares issued in connection with debt	60,000	400	59,600
Shares issued in connection with debt, (Shares)		400,000
Net loss	(5,597,300)			(5,597,300)
Balance at Dec. 31, 2011	474,484	66,814	6,138,916	(5,731,246)
Balance, (Shares) at Dec. 31, 2011		66,813,997
Proceeds from private placements of restricted common stock	6,889,990	34,430	6,855,560
Proceeds from private placements of restricted common stock, (Shares)		34,430,000
Offering costs	(178,800)		(178,800)
Shares issued to COO		750	(750)
Shares issued to COO, (Shares)		750,000
Shares issued to employee	2,700	10	2,690
Shares issued to employee, (Shares)		10,000
Shares issued in debt conversions	454,577	3,423	451,154
Shares issued in debt conversions, (Shares)		3,423,395
Shares issued in exchange for warrants	752,183	1,604	750,579
Shares issued in exchange for warrants, (Shares)	1,603,673	1,603,673
Shares issued for exercise for warrants	11,667	117	11,550
Shares issued for exercise for warrants, (Shares)		116,667
Vesting of options and shares issued to officers, directors, advisory board member, consultants and employees	359,497		359,497
Shares issued in connection with debt	1,346,139	2,885	1,343,254
Shares issued in connection with debt, (Shares)		2,885,550
Net loss	(3,914,460)			(3,914,460)
Balance at Dec. 31, 2012	6,197,977	110,033	15,733,650	(9,645,706)
Balance, (Shares) at Dec. 31, 2012		110,033,282
Shares issued to employee	178,820	1,338	177,482
Shares issued to employee, (Shares)		1,338,000
Shares issued to CEO
Shares issued to CEO, (Shares)
Shares issued for services	170	1	169
Shares issued for services, (Shares)		1,000
Vesting of options and shares issued to officers, directors, advisory board member, consultants and employees	928,832		928,832
Net loss	(2,854,316)			(2,854,316)
Balance at Sep. 30, 2013	$ 4,451,483	$ 111,372	$ 16,840,133	$ (12,500,022)
Balance, (Shares) at Sep. 30, 2013		111,372,282

XML

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets
Cash	$ 1,883,464	$ 3,979,662
Accounts receivable	214,740	201,579
Inventories	10,869	218,317
Prepaid expenses and other current assets	233,840	84,388
Total current assets	2,342,913	4,483,946
Fixed assets, net of accumulated depreciation	327,959	8,389
Intellectual property	2,000,000	2,000,000
Intangible assets	38,117	36,440
Total assets	4,708,989	6,528,775
Current liabilities
Accounts payable and accrued expenses	213,556	208,898
Total current liabilities	213,556	208,898
Derivatives liability	43,950	121,900
Total liabilities	257,506	330,798
Stockholders' equity
Preferred stock, $.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value, 300,000,000 shares authorized; 111,372,282 shares issued and outstanding at September 30, 2013 110,033,282 shares issued and outstanding at December 31, 2012	111,372	110,033
Additional paid-in capital	16,840,133	15,733,650
Deficit accumulated during development stage	(12,500,022)	(9,645,706)
Total stockholders' equity	4,451,483	6,197,977
Total liabilities and stockholders' equity	$ 4,708,989	$ 6,528,775

XML

Commitments, Contingencies and Other Comments (Details Textual) (USD $)	0 Months Ended			1 Months Ended		4 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended	9 Months Ended		12 Months Ended	9 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended		9 Months Ended		1 Months Ended			1 Months Ended		0 Months Ended	9 Months Ended	0 Months Ended
	Sep. 24, 2012	Feb. 10, 2012	Dec. 02, 2011	Sep. 24, 2012	Sep. 30, 2012	Sep. 30, 2012	Jul. 12, 2011	Jul. 12, 2011	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013 Operating Lease [Member] Option	Sep. 30, 2013 Employee Stock Option [Member]	Dec. 31, 2012 Employee Stock Option [Member]	Sep. 30, 2013 Minimum [Member] Employee Stock Option [Member]	Sep. 30, 2013 Maximum [Member] Employee Stock Option [Member]	Jul. 14, 2011 Dr. Louis Aronne - scientific advisory board [Member] Installments	Jul. 26, 2011 Dr. Robert Hariri - director [Member] Installments	Aug. 15, 2011 Dr. Peter Diamandis - director [Member] Installments	May 24, 2012 Dr. Buzz Aldrin - director [Member] Installments	Feb. 06, 2013 Dr. Sapna Srivastava - director [Member] Installments	May 16, 2012 Distribution Agreement [Member]	Sep. 30, 2013 Distribution Agreement [Member]	Sep. 30, 2013 Supply Agreement [Member]	Jun. 27, 2011 Sponsorship Agreement [Member]	Jun. 27, 2013 Sponsorship Agreement [Member]	Dec. 31, 2011 Sponsorship Agreement [Member]	Feb. 25, 2011 J.B. Bernstein [Member]	Feb. 25, 2011 Carlon Colker MD, FACN [Member]	Feb. 08, 2013 Peter A. Levy [Member]	Sep. 30, 2013 Peter A. Levy [Member]	Jan. 02, 2013 Glen R. Fleischer [Member]
Commitments, Contingencies and Other Comments (Textual)
Proceeds from future purchase																						$ 195,301
Term of distribution agreement																						The term of the Agreement provided for one year of exclusivity for MHP, which expired on September 29, 2013. While the Agreement remains in effect, the parties are currently negotiating a new agreement
Bank line of credit, agreement																							In October 2013, the Company was granted a $500,000 line of credit by City National Bank, that bears a per annum interest rate through April 15, 2014 equal to the prime rate, after which the rate changes to the prime rate plus 1.25 percent. As of the date of this report, the Company has not drawn on the line of credit.
Annual base salary																														200,000
Number of Options/Warrants									9,541,000					250,000																500,000
Term of agreement																								The term of the agreement is for two years, and will continue indefinitely until terminated by either party upon three months written notice
Term of employment agreement																									1 year			6 months		3 years		3 years
Description of base salary in case of employment termination any reason other than cause, death or disability																															Entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination
Description of base salary if employment terminated as a result of, a change of control																															Entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) $50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination
Consulting fees																												5,000
Annual base salary																									150,000							320,000
Description of cash compensation																									The agreement provided for cash compensation of $150,000 in three equal installments of $50,000, all of which was paid in 2011
Annual bonus in percentage																														100.00%		100.00%
Agreement contains customary extend period																														2 years
Renew agreement on same base salary for period																														1 year		1 year
Period of vested options expire termination																														12 months
Period for base salary from date of termination																														12 months
Term for notice of non renewal prior to the expiration date																														60 days		60 days
Royalties rate, per unit sold																									$ 0.50
Number of additional months thereafter																									12 months
Number of purchased shares of common stock to certain investors																									150,000
Shares issued upon conversion of warrants																									100,000
Number of warrants term																									2 years
Exercise price of warrants	$ 0.10	$ 0.10	$ 0.20	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.60																$ 1.00
Trading price of common stock on principal trading market, per share																									$ 2.00
Exchange for each share of common stock underlying the unexercised portion of the Warrants																									$ 1.00
Warrants, shares issued																									100,000		50,000
Warrants issued upon execution of the agreement, value																											40,900
Compensation shares of restricted common stock vesting																	100,000	100,000	100,000	100,000	100,000
Compensation shares of common stock option to purchase																	250,000	250,000	250,000	250,000	250,000
Compensation common stock at an exercise price																	$ 0.64	$ 0.69	$ 0.45	$ 0.14	$ 0.20
Period of common stock vesting																	10 years	10 years	10 years	10 years	10 years
Common stock exercise vesting																	Over a period of 3 years	Over a period of 3 years	Over a period of 3 years	Over a period of 3 years	Over a period of 3 years
Vesting terms range															3 years	4 years
Term of advisory board agreement																	5 years
Number of annual installments of restricted common stock purchase																	5	5	5	5	5
Restricted common stock issued, Value									40,337	445,063	457,279
Shares receive under terms of the offer letter									4,183,395		4,183,395																					5,000,000
Operating lease expiring												July 2017
Number of option to renew												2
Annual rent increases in percentage												3.00%
Operating lease period												3 years
Rent expense									44,018	22,155
Consulting agreement expire date																												Oct. 31, 2012
Share issued pursuant to agreement																													300,000
Number of warrant expired																									100,000
Derivative Liability																										$ 100,000

XML

Private Placements of Restricted Common Stock (Details) (USD $)	0 Months Ended	2 Months Ended	6 Months Ended	9 Months Ended		78 Months Ended
	Dec. 02, 2011	Mar. 31, 2012	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013		Apr. 11, 2007
Summary of proceeds from private placements
Shares						42,764,997
Gross Proceeds	$ 40,000	$ 102,500	$ 1,725,000		$ 6,869,990	$ 9,350,490
Related Warrant Liability								4,838,690
February 25, 2011 [Member]
Summary of proceeds from private placements
Shares						4,766,666
Gross Proceeds						1,430,000
Related Warrant Liability								2,350,251
May 31, 2011 [Member]
Summary of proceeds from private placements
Shares						1,409,999
Gross Proceeds						423,000
Related Warrant Liability								1,186,859
June 27, 2011 [Member]
Summary of proceeds from private placements
Shares						1,874,999
Gross Proceeds						562,500
Related Warrant Liability								1,243,838
July 12, 2011 [Member]
Summary of proceeds from private placements
Shares						83,333
Gross Proceeds						25,000
Related Warrant Liability								57,742
December 2, 2011 [Member]
Summary of proceeds from private placements
Shares						200,000
Gross Proceeds						40,000
Related Warrant Liability
February 10, 2012 [Member]
Summary of proceeds from private placements
Shares						3,250,000
Gross Proceeds						325,000
Related Warrant Liability
February 14, 2012 [Member]
Summary of proceeds from private placements
Shares						4,000,000
Gross Proceeds						400,000
Related Warrant Liability
March 7, 2012 [Member]
Summary of proceeds from private placements
Shares						1,000,000
Gross Proceeds						100,000
Related Warrant Liability
March 15, 2012 [Member]
Summary of proceeds from private placements
Shares						1,750,000
Gross Proceeds						175,000
Related Warrant Liability
March 22, 2012 [Member]
Summary of proceeds from private placements
Shares						2,400,000
Gross Proceeds						600,000
Related Warrant Liability
April 9, 2012 [Member]
Summary of proceeds from private placements
Shares						20,580,000
Gross Proceeds						5,144,990
Related Warrant Liability
April 24, 2012 [Member]
Summary of proceeds from private placements
Shares						250,000
Gross Proceeds				100,000	100,000	25,000
Related Warrant Liability
June 28, 2012 [Member]
Summary of proceeds from private placements
Shares						1,000,000
Gross Proceeds				600,000		100,000
Related Warrant Liability
July 6, 2012 [Member]
Summary of proceeds from private placements
Shares						200,000	[1]
Gross Proceeds				51,449,900
Related Warrant Liability

[1] * Shares issued under price protection provision of subscription agreement as described above.

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Tables)

9 Months Ended

Sep. 30, 2013

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of warrants issued to private placement and consultants

Grant Date	Number of Warrants Issued		Number of Warrants Exchanged, Exercised or Expired		Number of Warrants Outstanding as of September 30, 2013	Exercise Price Original/Repriced		Expiration Term in Years
February 25, 2011 (A)		4,766,666		4,766,666	-	$	0.60/$0.10	-
May 31, 2011  (A)		1,409,999		1,409,999	-	$	0.60/$0.10	-
June 27, 2011  (A)		1,874,999		1,874,999	-	$	0.60/$0.10	-
June 27, 2011 (B)		100,000		100,000	-	$	1.00	-
July 12, 2011  (A)		83,333		83,333	-	$	0.60/$0.10	-
December 23, 2011  (B)		50,000		-	50,000	$	1.00	.23

(A) Private placement warrants (these warrants were subject to down round full ratchet anti dilution provisions and the exercise price was adjusted to $0.10 per share in February 2012)

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

Summary of option/warrant activities

	Shares Under Warrants			Weighted Average Exercise Price Original/Repriced
Balance at January 1, 2012		8,284,997		$	0.61/$0.10
Warrants granted		-
Warrants exercised		(116,667	)
Warrants cancelled/exchanged/expired		(8,018,330	)
Balance at December 31, 2012		150,000		$	1.00
Warrants granted		-
Warrants exercised		-
Warrants cancelled/exchanged/expired		100,000		$	1.00
Balance at September 30, 2013		50,000		$	1.00

Summary of warrants/option outstanding and exercisable

Warrants Outstanding and Exercisable
Range of Exercise Price		Warrants Outstanding and Exercisable	Weighted Average Remaining Contractual Life
$	1.00	50,000	.23

Summary of assumptions used to value the warrants and the director/advisory board options

Grant Date		Number of Warrants Issued/ Outstanding		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
(A)	02/25/11		4,766,666	$	0.50	$	0.60		3.00		285.20	%		0.00	%		1.48	%
(A)	05/31/11		1,409,999	$	0.85	$	0.60		3.00		208.89	%		0.00	%		0.79	%
(A)	06/27/11		1,874,999	$	0.67	$	0.60		3.00		295.31	%		0.00	%		0.64	%
(A)	07/12/11		83,333	$	0.70	$	0.60		3.00		278.00	%		0.00	%		0.42	%
(B)	06/27/11		100,000	$	0.67	$	1.00		2.00		213.59	%		0.00	%		0.41	%
(B)	12/23/11		50,000	$	0.09	$	1.00		2.00		209.00	%		0.00	%		0.28	%

(A) Private placement warrant

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of option/warrant activities

	Shares Under Options		Weighted Average Exercise Price
Balance at January 1, 2012		1,250,000	$	0.61
Options granted		250,000	$	0.14
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		1,500,000	$	0.53
Options granted		-
Options exercised		-
Options cancelled/expired		-
Balance at September 30, 2013		1,500,000	$	0.53

Summary of warrants/option outstanding and exercisable

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.64		750,000		7.79	$	0.64		625,000		7.79
$	0.69		250,000		7.82	$	0.69		250,000		7.82
$	0.45		250,000		7.87	$	0.45		250,000		7.87
$	0.14		250,000		8.65	$	0.14		166,666		8.65

Summary of assumptions used to value the warrants and the director/advisory board options

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
07/14/11		750,000	$	0.64	$	0.64		10.00		287.00	%		0.00	%		2.98	%
07/26/11		250,000	$	0.69	$	0.69		10.00		285.00	%		0.00	%		2.99	%
08/15/11		250,000	$	0.45	$	0.45		10.00		284.00	%		0.00	%		2.29	%
05/24/12		250,000	$	0.14	$	0.14		10.00		187.00	%		0.00	%		1.77	%

2012 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of option/warrant activities

	Shares Under Options			Weighted Average Exercise Price
Balance at January 1, 2012		-
Options granted		8,000		$	0.20
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		8,000		$	0.20
Options granted		9,535,000		$	0.30
Options exercised		-
Options cancelled/expired		(2,000	)	$	0.20
Balance at September 30, 2013		9,541,000		$	0.30

Summary of warrants/option outstanding and exercisable

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.14		150,000		9.51	$	0.14		-		-
$	0.19		150,000		9.76	$	0.19		-		-
$	0.20		606,000		9.31	$	0.20		159,333		9.32
$	0.22		150,000		9.28	$	0.22		-		-
$	0.25		3,485,000		9.40	$	0.25		358,332		9.29
$	0.35		5,000,000		9.36	$	0.35		-		-

Summary of assumptions used to value the warrants and the director/advisory board options

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
11/20/12		6,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.66	%
01/01/13		150,000	$	0.19	$	0.22		10.00		164.00	%		0.00	%		2.00	%
01/07/13		350,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.92	%
01/07/13		2,000,000	$	0.20	$	0.25		10.00		166.00	%		0.00	%		1.92	%
02/07/13		5,000,000	$	0.20	$	0.35		10.00		164.00	%		0.00	%		1.99	%
02/07/13		450,000	$	0.20	$	0.25		10.00		164.00	%		0.00	%		1.99	%
02/08/13		250,000	$	0.19	$	0.20		10.00		164.00	%		0.00	%		2.00	%
02/28/13		100,000	$	0.20	$	0.25		10.00		158.00	%		0.00	%		1.89	%
04/01/13		150,000	$	0.14	$	0.14		10.00		160.00	%		0.00	%		1.86	%
05/06/13		400,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.80	%
05/20/13		10,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.97	%
05/21/13		200,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.94	%
05/24/13		5,000	$	0.13	$	0.25		10.00		160.00	%		0.00	%		2.01	%
06/10/13		100,000	$	0.16	$	0.25		10.00		160.00	%		0.00	%		2.22	%
07/01/13		150,000	$	0.19	$	0.19		10.00		159.00	%		0.00	%		2.50	%
08/21/13		220,000	$	0.17	$	0.25		10.00		157.00	%		0.00	%		2.87	%

Summary of stock options issued to stockholders

Issued to	Number of Options		Range of Exercise Price		Expiration Term in Years
Employees		112,000	$	0.20 to 0.25	10
Consultants		1,327,000	$	0.20 to 0.25	10
Officers		1,152,000	$	0.20 to 0.25	10
Directors		6,700,000	$	0.14 to 0.35	10
Scientific Advisory Board Member		250,000	$	0.25	10
Total		9,541,000

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details Textual) (USD $)	0 Months Ended				1 Months Ended				4 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended		78 Months Ended
	Jan. 07, 2013	Sep. 24, 2012	Feb. 10, 2012	Dec. 02, 2011	Sep. 24, 2012	Sep. 30, 2012	Jun. 27, 2012	Jun. 30, 2012	Sep. 30, 2012	Jul. 12, 2011	Jul. 12, 2011	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Nov. 29, 2011
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of Options/Warrants												9,541,000
Warrants/Options granted, Shares Under Warrants/Options												9,541,000
Expected Term										3 years	3 years
Price per share																	$ 0.15
Restricted common stock issued, Shares												4,183,395		4,183,395
Restricted common stock issued, Value												$ 40,337	$ 445,063	$ 457,279
Additionally share issued to officer	5,000,000
Warrant issued for purchase of restricted common stock															8,134,997
Number of warrants exchanged						488,331		7,529,999
Shares issued in exchange for warrants, (Shares)		97,669			97,669		1,506,004	1,506,004	1,603,673					1,603,673
Derivatives charges and credits												22,050	(176)			(1,521,483)
Warrants exercised share		116,667			116,667				116,667					116,667
Exercise price of warrants		$ 0.10	$ 0.10	$ 0.20	$ 0.10	$ 0.10			$ 0.10	$ 0.10	$ 0.10	$ 0.60
Warrants exercised share received		116,667			116,667
Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Price per share												$ 0.07				$ 0.07
Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Price per share												$ 0.45				$ 0.45
Director And Consultant [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Restricted common stock issued, Shares												1,339,000
Restricted common stock issued, Value												94,549
Director And Consultant [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Price per share												$ 0.12				$ 0.12
Director And Consultant [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Price per share												$ 0.20				$ 0.20
Warrant [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of Options/Warrants															8,284,997
Exercise Price												$ 1.00
Options outstanding												50,000		150,000	8,284,997	50,000
Weighted average exercise price, per share												$ 1.00		$ 1.00		$ 1.00
Warrants/Options granted, Shares Under Warrants/Options															8,284,997
Warrant [Member] | Original [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Weighted average exercise price, per share															$ 0.61
Warrant [Member] | Repriced [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Weighted average exercise price, per share															$ 0.10
2012 Equity Incentive Plan [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of Options/Warrants												9,541,000
Number of shares vested												517,665				517,665
Number of shares non-vested												9,023,335				9,023,335
Vested options, Weighted average remaining contractual life												9 years 3 months 18 days
Weighted average exercise price, per share												$ 0.23				$ 0.23
Common stock reserved for issuance												10,000,000				10,000,000
Warrants/Options granted, Shares Under Warrants/Options												9,541,000
2012 Equity Incentive Plan [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range												0 years
2012 Equity Incentive Plan [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range												5 years
Stock Options [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of Options/Warrants														250,000
Exercise Price														$ 0.14
Options outstanding												15,000,000		1,500,000	1,250,000	15,000,000
Number of shares vested												1,291,666				1,291,666
Number of shares non-vested												208,334				208,334
Options outstanding, Weighted average remaining contractual life												7 years 11 months 12 days
Vested options, Weighted average remaining contractual life												7 years 11 months 1 day
Weighted average exercise price, per share												$ 0.53		$ 0.53	$ 0.61	$ 0.53
Warrants/Options granted, Shares Under Warrants/Options														250,000
Aggregate intrinsic value of outstanding options
Aggregate intrinsic value of exercisable options
Aggregate unvested cost of the options												79,861				79,861
Options, Intrinsic value												$ 1,116,174				$ 1,116,174
Market price for our common stock												$ 0.12				$ 0.12
Stock Options [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range												3 years
Stock Options [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range												4 years

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 6)	9 Months Ended
	Sep. 30, 2013
$ 0.64 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.64
Options outstanding	750,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 9 months 15 days
Options exercisable, Range of Exercise Price	0.64
Options Exercisable, Options Exercisable	625,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 9 months 15 days
$ 0.69 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.69
Options outstanding	250,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 9 months 26 days
Options exercisable, Range of Exercise Price	0.69
Options Exercisable, Options Exercisable	250,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 9 months 26 days
$ 0.45 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.45
Options outstanding	250,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 10 months 13 days
Options exercisable, Range of Exercise Price	0.45
Options Exercisable, Options Exercisable	250,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 10 months 13 days
$ 0.14 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price	0.14
Options outstanding	250,000
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 7 months 24 days
Options exercisable, Range of Exercise Price	0.14
Options Exercisable, Options Exercisable	166,666
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 7 months 24 days

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 2) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Warrant [Member]
Summary of warrants outstanding and exercisable
Range of Exercise Price	$ 1.00
Warrants Outstanding and Exercisable	50,000
Weighted Average Remaining Contractual Life	2 months 23 days

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 3) (USD $)	4 Months Ended	6 Months Ended	9 Months Ended		12 Months Ended		9 Months Ended
	Jul. 12, 2011	Jul. 12, 2011	Sep. 30, 2013	Sep. 30, 2013 Warrant [Member]	Dec. 31, 2012 Warrant [Member]	Dec. 31, 2011 Warrant [Member]	Sep. 30, 2013 Warrant [Member] February 25, 2011 (A) [Member]	Sep. 30, 2013 Warrant [Member] May 31, 2011 (A) [Member]	Sep. 30, 2013 Warrant [Member] June 27, 2011 (A) [Member]	Sep. 30, 2013 Warrant [Member] July 12, 2011 (A) [Member]	Sep. 30, 2013 Warrant [Member] June 27, 2011 (B) [Member]	Sep. 30, 2013 Warrant [Member] December 23, 2011 (B) [Member]
Assumption used to value warrants using Black-Scholes pricing model
Number of Options/Warrants			9,541,000			8,284,997	4,766,666	1,409,999	1,874,999	83,333	100,000	50,000
Stock Price on Measurement Date							$ 0.50	$ 0.85	$ 0.67	$ 0.70	$ 0.67	$ 0.09
Exercise Price				$ 1.00			$ 0.60	$ 0.60	$ 0.60	$ 0.60	$ 1.00	$ 1.00
Expected Term	3 years	3 years					3 years	3 years	3 years	3 years	2 years	2 years
Expected Volatility							285.20%	208.89%	295.31%	278.00%	213.59%	209.00%
Dividend Yield							0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Risk Free Rate							1.48%	0.79%	0.64%	0.42%	0.41%	0.28%

XML

Notes and Loans Payable

9 Months Ended

Sep. 30, 2013

Notes and Loans Payable [Abstract]

NOTES AND LOANS PAYABLE

NOTE 5 - NOTES AND LOANS PAYABLE

Convertible Notes Payable

On November 29, 2011, the Company received aggregate proceeds of $400,000 from two individuals ($150,000 of which was from a director of the Company) on notes payable bearing interest at 18%, due on May 29, 2012 and convertible into common stock at the rate of $0.20 per share or an adjusted lower rate determined by reference to a subsequent qualified financing.  As additional consideration, the note holders were issued an aggregate of 400,000 shares of common stock valued at $0.15 per share for an aggregate of $60,000.  The value of the shares issued were recorded as deferred financing costs and were amortized over the six month term of the notes.  There were no unamortized balances at September 30, 2013 and December 31, 2012, respectively.  Related amortization expense was $34,000 for the nine months ended September 30, 2012.

On June 28, 2012, the aggregate principal of $400,000 and the accrued interest of $41,800 on the notes were converted into 2,209,000 shares of restricted common stock at $0.20 per share, the value of which exceeded the principal and accrued interest by $618,520 on the conversion date. This amount was recorded as interest expense in the second quarter of 2012.  The amount recorded as interest expense for the nine months ended September 30, 2012 was $654,123.

Notes Payable to Director

A director loaned the Company $99,500, of which $60,000 was advanced on September 29, 2011 and was evidenced by an unsecured note payable which was due on October 29, 2011 bearing interest at 3%; $10,000 was advanced in October 2011; $10,000 was advanced in December 2011 for direct payment to a vendor and $19,500 of which was advanced in January 2012 for direct payments to vendors.  On June 28, 2012, the principal plus accrued interest on the loans and advances of $1,961 (aggregate of $101,461) were converted into 507,306 shares of common stock at $0.20 per share, the value of which exceeded the principal and accrued interest by $142,046 on the conversion date.  This amount was recorded as interest expense in the second quarter of 2012. The amount recorded as interest expense for the nine months ended September 30, 2012 was $143,557.

Note Payable to Shareholders

On May 20, 2010, the Company issued a note for $7,500 bearing interest at 5% in exchange for a shareholder's payment of $7,500 on an open account payable balance. The note was due and payable upon demand.  On September 20, 2012, the aggregate principal and accrued interest  were converted into 30,000 shares of restricted common stock. The amount recorded as interest expense for the nine months ended September 30, 2012 was $188.

On June 15, 2012, a stockholder loaned the Company $65,000, payable on July 15, 2012 without interest.  The loan was repaid in July 2012.

XML

Private Placements of Restricted Common Stock (Details Textual) (USD $)	0 Months Ended			1 Months Ended				2 Months Ended	4 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended	78 Months Ended	9 Months Ended		1 Months Ended	9 Months Ended		78 Months Ended	9 Months Ended	78 Months Ended	9 Months Ended	78 Months Ended
	Sep. 24, 2012	Feb. 10, 2012	Dec. 02, 2011	Sep. 24, 2012	Sep. 30, 2012	Jun. 27, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2012	Jul. 12, 2011	Jul. 12, 2011	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2007 Private Placement [Member]	Jul. 12, 2011 Private Placement [Member]	Apr. 30, 2007 Founder [Member]	Sep. 30, 2013 April 9, 2012 [Member]	Sep. 30, 2012 April 9, 2012 [Member]	Sep. 30, 2013 April 9, 2012 [Member]	Sep. 30, 2013 June 28, 2012 [Member]	Sep. 30, 2013 June 28, 2012 [Member]	Sep. 30, 2013 July 6, 2012 [Member]	Sep. 30, 2013 July 6, 2012 [Member]
Private Placements of Restricted Common Stock (Textual)
Number of common stock sold to founders																	21,000,000		28,000,000
Cash proceeds																	$ 75,000		$ 5,000
Stockholders' equity, stock split													14 shares for 1 basis				1 to 14		1 to 14
Number of purchased shares of common stock to certain investors																		8,134,997
Gross Proceeds			40,000					102,500				1,725,000		6,869,990		9,350,490				100,000	100,000	25,000	600,000	100,000	51,449,900
Restricted common stock share issued in private placement								10,250,000												1,000,000			2,400,000		20,580,000
Common stock and warrants, share issued									8,018,330		8,134,997
Expected Term										3 years	3 years
Exercise price of warrants	$ 0.10	$ 0.10	$ 0.20	$ 0.10	$ 0.10				$ 0.10	$ 0.10	$ 0.10		$ 0.60
Shares issued through private placement			200,000
Exercise price of the financing instrument for anti-dilution protection of warrants			P10M
Additional shares issued to the investor as a result of the price protection provision							200,000
Shares issued in exchange for warrants, (Shares)	97,669			97,669		1,506,004	1,506,004		1,603,673						1,603,673
Warrants/Options cancelled/expired				488,331		7,529,999
Warrants exercised share	116,667			116,667					116,667						116,667
Amount of exercised warrants									$ 11,667
Warrants exercised share received	116,667			116,667

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details 9) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of stock option activities
Warrants/Options granted, Shares Under Warrants/Options	9,541,000
2012 Equity Incentive Plan [Member]
Summary of stock option activities
Beginning Balance, Shares Under Options/Warrants	8,000
Warrants/Options granted, Shares Under Warrants/Options	9,535,000	8,000
Options/Warrants exercised, Share Under Options/Warrants
Warrants/Options cancelled/expired, Shares Under Options	(2,000)
Balance, Shares Under Options/Warrants	9,541,000	8,000
Beginning Balance, Weighted Average Exercise Price	$ 0.20
Warrants/Options granted, Weighted Average Exercise Price	$ 0.30	$ 0.20
Warrants/Options exercised, Weighted Average Exercise Price
Warrants/Options cancelled/expired, Weighted Average Exercise Price	$ 0.20
Balance, Weighted Average Exercise Price	$ 0.30	$ 0.20

XML

Intellectual Property Purchase Agreement

9 Months Ended

Sep. 30, 2013

Intellectual Property Purchase Agreement [Abstract]

INTELLECTUAL PROPERTY PURCHASE AGREEMENT

NOTE 8 – INTELLECTUAL PROPERTY PURCHASE AGREEMENT

On February 25, 2011, the Company, Atlas Acquisition Corp., a wholly-owned subsidiary of the Company formed in February 2011 (“Atlas Sub”), and Peak Wellness, Inc. (“Peak”), entered into and consummated an Intellectual Property Purchase Agreement (the “Purchase Agreement”), pursuant to which Atlas Sub purchased certain intellectual property assets from Peak (the “Acquisition”).  Pursuant to the Purchase Agreement, the Company acquired from Peak all intellectual property pertaining to MYO-T12, a natural-myostatin inhibitor, including the formula and process for making MYO-T12, certain trademarks, trade secrets, patent applications and certain domain names.  The aggregate consideration for MYO-T12 was $4,662,000 paid in cash, a promissory note and shares of common stock. The contractually stated purchase price for the assets was $1,150,000, of which $450,000 was paid in cash and $700,000 via the issuance of the promissory note.  Additionally, the Company issued 7,024,000 shares of common stock with an aggregate fair value of $3,512,000 to Peak as part of the purchase price of MYO-T12, representing 12% of the fully diluted voting common stock of the Company on the date of the Acquisition.

In connection with the Purchase Agreement, the Company issued a secured promissory note to Peak (the “Promissory Note”) in the amount of $700,000 with interest accruing at an interest rate of 3% per annum.  The Promissory Note was payable in two installments as follows: $350,000 plus accrued interest was due within 180 days after the closing date of the Agreement (originally August 25, 2011 but extended to the earlier of November 30, 2011 or the closing of a certain financing and paid on November 29, 2011) and $350,000 plus accrued interest was due on the first anniversary of the closing date of the Agreement and paid on February 21, 2012.

In connection with the Purchase Agreement and the Promissory Note, the Company entered into a security agreement with Peak to secure the payments due under the Promissory Note (the “Security Agreement”).  Pursuant to the Security Agreement, the Company granted Peak a continuing security interest in the assets purchased from Peak. The Security Agreement also secured all of the Company’s obligations to Peak, whether related or unrelated to the Promissory Note. The security interest was released in February 2012 upon payment of the final installment of the Promissory Note.  On the closing date of the Acquisition, new officers and a new director were appointed to serve the Company.

The Company completed its first annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011. Based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues from sales of MYO-T12 and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property intangible assets exceeded its fair value.  Accordingly, the Company recorded noncash impairment charges totaling $2,662,000 in 2011, reducing the MYO-T12 intellectual property asset to its fair value of $2,000,000.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was $2,000,000.  Management performed their annual and quarterly reviews of the intellectual property and determined no impairment existed and there was no change to the carrying value for the year ended December 31, 2012 and the nine months ended September 30, 2013, respectively.

XML

Advances, Accounts Payable and Accrued Expenses - Related Parties

9 Months Ended

Sep. 30, 2013

Advances, Accounts Payable and Accrued Expenses - Related Parties [Abstract]

ADVANCES, ACCOUNTS PAYABLE AND ACCRUED EXPENSES - RELATED PARTIES

NOTE 4 - ADVANCES, ACCOUNTS PAYABLE AND ACCRUED EXPENSES -  RELATED PARTIES

As of September 30, 2013 and December 31, 2012, there are no amounts due to related parties for advances, accounts payable and accrued expenses.

XML

Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended		78 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash Flows from Operating Activities
Net loss	$ (2,854,316)	$ (2,896,286)	$ (12,500,022)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	25,553	771	27,002
Amortization		49,451	80,000
Stock based compensation	1,042,793	707,143	4,390,162
Loss on debt conversion		760,566	760,566
Impairment charges			2,662,000
Accounts payable paid in stock		7,500
Interest expense paid in stock		43,762	43,762
Related parties paid in stock		71,706
Derivatives charges and credits	22,050	(176)	(1,521,483)
Changes in operating assets and liabilities
(Increase) decrease in accounts receivable	(13,161)	(198,042)	(214,740)
(Increase) decrease in inventories	207,448	341,538	(10,869)
(Increase) decrease in prepaid expenses and other assets	(84,425)	87,546	(125,994)
Increase (decrease) in accounts payable and accrued expenses	(95,342)	(363,175)	25,365
Net cash used in operating activities	(1,749,400)	(1,387,696)	(6,384,251)
Cash Flows from Investing Activities
Acquisition of intellectual property			(450,000)
Acquisition of fixed assets	(345,121)	(2,044)	(354,959)
Acquisition of intangible assets	(1,677)		(38,117)
Decrease in security deposits		10,000
Net cash used in investing activities	(346,798)	7,956	(843,076)
Cash Flows from Financing Activities
(Repayments to) advances from related parties			140,434
Note borrowings			19,500
Repayment of notes payable		(350,000)	(807,500)
Proceeds from (Repayments of) issuance of notes		(40,500)	540,000
Proceeds from issuance of stock to initial stockholders			80,000
Proceeds from exercise of warrants		11,667	11,667
Proceeds from private placement of common stock		6,869,990	9,350,490
Offering costs		(178,800)	(223,800)
Net cash provided by financing activities		6,312,357	9,110,791
Net increase/(decrease) in cash	(2,096,198)	4,932,617	1,883,464
Cash at beginning of the period	3,979,662	61,266
Cash at end of the period	1,883,464	4,993,883	1,883,464
Supplemental Disclosure of Cash Flow Information:
Total Cash paid for franchise taxes	2,650	2,578	6,028
Total Cash paid for Interest	10	15,892	15,902
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Offering costs paid by stockholder			25,000
Conversion of stockholder loan and interest into common stock		546,743	549,487
Conversion of stockholder loan into capital - no shares issued			22,256
Conversion of 488,331 warrants into 97,669 common shares		44,050	44,050
Conversion of 7,529,999 warrants into 1,506,004 common shares		722,882	722,882
Note payable - insurance financing			42,500
Note issued for accounts payable			7,500
Acquisition of intellectual property through note payable			700,000
Financing costs through issuance of restricted common stock		$ 20,000	$ 80,000

XML

Income Taxes (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Deferred tax assets:
Goodwill	$ 588,015	$ 672,348
Net operating losses	3,104,230	2,133,004
Other	1,582	1,542
Total deferred tax assets	3,693,827	2,806,894
Valuation allowance	(3,681,438)	(2,804,632)
Total net deferred tax assets	12,389	2,262
Deferred tax liabilities:
Depreciation	(12,389)	(2,262)
Total deferred tax liabilities	(12,389)	(2,262)
Net deferred tax asset

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	9,541,000
Warrant [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants			8,284,997
Number of Warrants Outstanding as of September 30, 2013	50,000	150,000	8,284,997
Exercise Price	$ 1.00
Warrant [Member] | February 25, 2011 (A) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	4,766,666
Number of Warrants Exchanged or Exercised	4,766,666
Number of Warrants Outstanding as of September 30, 2013
Exercise Price	$ 0.60
Warrant [Member] | February 25, 2011 (A) [Member] | Original [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.60
Warrant [Member] | February 25, 2011 (A) [Member] | Repriced [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.10
Warrant [Member] | May 31, 2011 (A) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	1,409,999
Number of Warrants Exchanged or Exercised	1,409,999
Number of Warrants Outstanding as of September 30, 2013
Exercise Price	$ 0.60
Warrant [Member] | May 31, 2011 (A) [Member] | Original [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.60
Warrant [Member] | May 31, 2011 (A) [Member] | Repriced [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.10
Warrant [Member] | June 27, 2011 (A) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	1,874,999
Number of Warrants Exchanged or Exercised	1,874,999
Number of Warrants Outstanding as of September 30, 2013
Exercise Price	$ 0.60
Warrant [Member] | June 27, 2011 (A) [Member] | Original [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.60
Warrant [Member] | June 27, 2011 (A) [Member] | Repriced [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.10
Warrant [Member] | June 27, 2011 (B) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	100,000
Number of Warrants Exchanged or Exercised	100,000
Number of Warrants Outstanding as of September 30, 2013
Exercise Price	$ 1.00
Warrant [Member] | July 12, 2011 (A) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	83,333
Number of Warrants Exchanged or Exercised	83,333
Number of Warrants Outstanding as of September 30, 2013
Exercise Price	$ 0.60
Warrant [Member] | July 12, 2011 (A) [Member] | Original [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.60
Warrant [Member] | July 12, 2011 (A) [Member] | Repriced [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price	$ 0.10
Warrant [Member] | December 23, 2011 (B) [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Options/Warrants	50,000
Number of Warrants Exchanged or Exercised
Number of Warrants Outstanding as of September 30, 2013	50,000
Exercise Price	$ 1.00
Expiration Term in Years	2 months 23 days

XML

Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 11 - SUBSEQUENT EVENTS

NONE

XML

Warrants, Options, Equity Incentive Plan and Stock Issuances

9 Months Ended

Sep. 30, 2013

Warrants, Options, Equity Incentive Plan and Stock Issuances [Abstract]

WARRANTS, OPTIONS, EQUITY INCENTIVE PLAN AND STOCK ISSUANCES

NOTE 7 - WARRANTS, OPTIONS, EQUITY INCENTIVE PLAN AND STOCK ISSUANCES

Warrants

During the year ended December 31, 2011, the Company issued a total of 8,284,997 warrants to purchase restricted common stock.  Of those warrants, 8,134,997 were issued to private placement investors and included down round full ratchet anti-dilution provisions requiring periodic repricing if shares are later offered at lower prices.  In June 2012, holders of 7,529,999 warrants received 1,506,004 shares of restricted common stock in exchange for those warrants.  In September 2012, holders of 488,331 warrants received 97,669 shares of restricted common stock in exchange for such warrants and a holder of 116,667 warrants exercised such warrants at $0.10/share and received 116,667 shares of restricted common stock. During the year ended December 31, 2012 and nine months ended September 30, 2013, no warrants were issued. 

The following table summarizes the total warrants issued to private placement investors and consultants.    During the nine months ended September 30, 2013, no warrants were issued.  Derivative charges were $22,050 and ($177) for the nine months ended September 30, 2013 and 2012, respectively. The number of warrants outstanding as of September 30, 2013 is 50,000.

Grant Date	Number of Warrants Issued		Number of Warrants Exchanged, Exercised or Expired		Number of Warrants Outstanding as of September 30, 2013	Exercise Price Original/Repriced		Expiration Term in Years
February 25, 2011 (A)		4,766,666		4,766,666	-	$	0.60/$0.10	-
May 31, 2011  (A)		1,409,999		1,409,999	-	$	0.60/$0.10	-
June 27, 2011  (A)		1,874,999		1,874,999	-	$	0.60/$0.10	-
June 27, 2011 (B)		100,000		100,000	-	$	1.00	-
July 12, 2011  (A)		83,333		83,333	-	$	0.60/$0.10	-
December 23, 2011  (B)		50,000		-	50,000	$	1.00	.23

(A) Private placement warrants (these warrants were subject to down round full ratchet anti dilution provisions and the exercise price was adjusted to $0.10 per share in February 2012)

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

The following table summarizes the activities in warrants for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Warrants			Weighted Average Exercise Price Original/Repriced
Balance at January 1, 2012		8,284,997		$	0.61/$0.10
Warrants granted		-
Warrants exercised		(116,667	)
Warrants cancelled/exchanged/expired		(8,018,330	)
Balance at December 31, 2012		150,000		$	1.00
Warrants granted		-
Warrants exercised		-
Warrants cancelled/exchanged/expired		100,000		$	1.00
Balance at September 30, 2013		50,000		$	1.00

The following table summarizes information about warrants outstanding and exercisable at September 30, 2013.  As all warrants currently outstanding are fully and immediately vested at issuance, the information for both outstanding and exercisable are identical.

Warrants Outstanding and Exercisable
Range of Exercise Price		Warrants Outstanding and Exercisable	Weighted Average Remaining Contractual Life
$	1.00	50,000	.23

The following table summarizes the assumptions used to value the warrants using the Black-Scholes option pricing model:

Grant Date		Number of Warrants Issued/ Outstanding		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
(A)	02/25/11		4,766,666	$	0.50	$	0.60		3.00		285.20	%		0.00	%		1.48	%
(A)	05/31/11		1,409,999	$	0.85	$	0.60		3.00		208.89	%		0.00	%		0.79	%
(A)	06/27/11		1,874,999	$	0.67	$	0.60		3.00		295.31	%		0.00	%		0.64	%
(A)	07/12/11		83,333	$	0.70	$	0.60		3.00		278.00	%		0.00	%		0.42	%
(B)	06/27/11		100,000	$	0.67	$	1.00		2.00		213.59	%		0.00	%		0.41	%
(B)	12/23/11		50,000	$	0.09	$	1.00		2.00		209.00	%		0.00	%		0.28	%

(A) Private placement warrants

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

Options

The Company has issued an aggregate of 1,500,000 options to purchase restricted common stock to certain directors and scientific advisory board members (see Note 10 - Commitments, Contingencies and Other Comments – Director Agreements) prior to the adoption of the 2012 Equity Incentive Plan (the “Plan”).  For options issued under the Equity Incentive Plan, see “Equity Incentive Plan” below.

The following table summarizes the activities in stock options (outside the Plan) for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Options		Weighted Average Exercise Price
Balance at January 1, 2012		1,250,000	$	0.61
Options granted		250,000	$	0.14
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		1,500,000	$	0.53
Options granted		-
Options exercised		-
Options cancelled/expired		-
Balance at September 30, 2013		1,500,000	$	0.53

At September 30, 2013, the weighted-average remaining term of the options was 7.95 years.  As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was $NIL.  The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option.  The market price for our common stock at September 30, 2013 was $0.12.  The aggregate unvested cost of the options at September 30, 2013 was $79,861.

The following table summarizes the assumptions used to value the director/advisory board options using the Black-Scholes option pricing model:

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
07/14/11		750,000	$	0.64	$	0.64		10.00		287.00	%		0.00	%		2.98	%
07/26/11		250,000	$	0.69	$	0.69		10.00		285.00	%		0.00	%		2.99	%
08/15/11		250,000	$	0.45	$	0.45		10.00		284.00	%		0.00	%		2.29	%
05/24/12		250,000	$	0.14	$	0.14		10.00		187.00	%		0.00	%		1.77	%

The following table summarizes information about the options (outside the Plan) outstanding and exercisable at September 30, 2013 by the directors and scientific advisory board members:

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.64		750,000		7.79	$	0.64		625,000		7.79
$	0.69		250,000		7.82	$	0.69		250,000		7.82
$	0.45		250,000		7.87	$	0.45		250,000		7.87
$	0.14		250,000		8.65	$	0.14		166,666		8.65

As of September 30, 2013, 1,291,666 options have vested and 208,334 options remain unvested. The vesting terms range from 3 to 4 years and the vested options have a weighted average remaining term of 7.92 years and a weighted average exercise price of $0.55 per share.

Equity Incentive Plan

On September 24, 2012, the Company’s board of directors adopted the 2012 Equity Incentive Plan (the "Plan"), which was adopted by stockholders on November 20, 2012.  The Company believes that such awards better align the interests of its employees and directors with those of its shareholders.  The Company has reserved 10,000,000 shares of common stock under the Plan.  As of September 30, 2013, options to purchase 9,541,000 shares of the Company's stock have been granted under the Plan, as set forth in the table below:

Issued to	Number of Options		Range of Exercise Price		Expiration Term in Years
Employees		112,000	$	0.20 to 0.25	10
Consultants		1,327,000	$	0.20 to 0.25	10
Officers		1,152,000	$	0.20 to 0.25	10
Directors		6,700,000	$	0.14 to 0.35	10
Scientific Advisory Board Member		250,000	$	0.25	10
Total		9,541,000

The fair value of each option award is estimated on the date of grant using a Black Scholes model that uses variables noted in the following table.  Our determination of fair value is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury 10-year note in effect at the time of the grant.

The following table summarizes the assumptions used to value the Plan options using the Black-Scholes option pricing model:

Grant Date	Number of Options		Stock Price on Measurement Date		Exercise Price		Expected Term		Expected Volatility			Dividend Yield			Risk Free Rate
11/20/12		6,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.66	%
01/01/13		150,000	$	0.19	$	0.22		10.00		164.00	%		0.00	%		2.00	%
01/07/13		350,000	$	0.20	$	0.20		10.00		166.00	%		0.00	%		1.92	%
01/07/13		2,000,000	$	0.20	$	0.25		10.00		166.00	%		0.00	%		1.92	%
02/07/13		5,000,000	$	0.20	$	0.35		10.00		164.00	%		0.00	%		1.99	%
02/07/13		450,000	$	0.20	$	0.25		10.00		164.00	%		0.00	%		1.99	%
02/08/13		250,000	$	0.19	$	0.20		10.00		164.00	%		0.00	%		2.00	%
02/28/13		100,000	$	0.20	$	0.25		10.00		158.00	%		0.00	%		1.89	%
04/01/13		150,000	$	0.14	$	0.14		10.00		160.00	%		0.00	%		1.86	%
05/06/13		400,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.80	%
05/20/13		10,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.97	%
05/21/13		200,000	$	0.12	$	0.25		10.00		161.00	%		0.00	%		1.94	%
05/24/13		5,000	$	0.13	$	0.25		10.00		160.00	%		0.00	%		2.01	%
06/10/13		100,000	$	0.16	$	0.25		10.00		160.00	%		0.00	%		2.22	%
07/01/13		150,000	$	0.19	$	0.19		10.00		159.00	%		0.00	%		2.50	%
08/21/13		220,000	$	0.17	$	0.25		10.00		157.00	%		0.00	%		2.87	%

The following table summarizes the activities in stock options issued under the Plan during 2012 and during the nine month period ended September 30, 2013:

	Shares Under Options			Weighted Average Exercise Price
Balance at January 1, 2012		-
Options granted		8,000		$	0.20
Options exercised		-
Options cancelled/expired		-
Balance at December 31, 2012		8,000		$	0.20
Options granted		9,535,000		$	0.30
Options exercised		-
Options cancelled/expired		(2,000	)	$	0.20
Balance at September 30, 2013		9,541,000		$	0.30

At September 30, 2013, the weighted-average remaining term of the options was 9.38 years.  As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was $NIL.  The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option.  The market price for our common stock at September 30, 2013 was $0.12.  The aggregate unvested cost of the options at September 30, 2013 was $1,116,174.

The following table summarizes information about options outstanding and exercisable at September 30, 2013 that were granted under the Plan:

Options Outstanding						Options Exercisable
Range of Exercise Price		Options Outstanding		Weighted Average Remaining Contractual Life		Range of Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life
$	0.14		150,000		9.51	$	0.14		-		-
$	0.19		150,000		9.76	$	0.19		-		-
$	0.20		606,000		9.31	$	0.20		159,333		9.32
$	0.22		150,000		9.28	$	0.22		-		-
$	0.25		3,485,000		9.40	$	0.25		358,332		9.29
$	0.35		5,000,000		9.36	$	0.35		-		-

As of September 30, 2013, 517,665 options have vested and 9,023,335 options remain unvested.  The vesting terms range from zero to 5 years and the vested options have a weighted average remaining term of 9.30 years and a weighted average exercise price of $0.23 per share.

Stock Issuances

During the year ended December 31, 2012, the Company issued an aggregate of 4,183,395 shares of restricted common stock to consultants, a director, an employee and officers for services provided to the Company.  The shares issued were valued at trading prices on the date of issuance between $0.07 and $0.45 per share.  The compensation cost as a result of the issuance and vesting of such shares are aggregate charges of $40,337 and $445,063 for the nine month periods ended September 30, 2013 and 2012, respectively.  The shares issued to one of our officers and a director are subject to certain vesting requirements.

During the nine months ended September 30, 2013, the Company issued an aggregate of 1,339,000 shares of restricted common stock to a director, an employee and consultants.  All such shares were valued at trading prices on the date of issuance between $0.12 and $0.20 per share,  The compensation cost as a result of the issuance and vesting of such shares is an aggregate charge of $94,549 for the nine month period ended September 30, 2013.  Additionally, on January 7, 2013, the Company issued 5,000,000 shares to an officer which were subsequently cancelled in April 2013 upon the termination of his employment with the Company.

XML

Private Placements of Restricted Common Stock (Tables)

9 Months Ended

Sep. 30, 2013

Private Placements of Restricted Common Stock [Abstract]

Summary of proceeds from private placements

Date	Shares		Gross Proceeds		Related Warrant Liability at Inception		Related Warrant Liability at September 30, 2013
February 25, 2011		4,766,666	$	1,430,000	$	2,350,251	$	-
May 31, 2011		1,409,999		423,000		1,186,859		-
June 27, 2011		1,874,999		562,500		1,243,838		-
July 12, 2011		83,333		25,000		57,742		-
December 2, 2011		200,000		40,000		-		-
February 10, 2012		3,250,000		325,000		-		-
February 14, 2012		4,000,000		400,000		-		-
March 7, 2012		1,000,000		100,000		-		-
March 15, 2012		1,750,000		175,000		-		-
March 22, 2012		250,000		25,000		-		-
April 9, 2012		1,000,000		100,000		-		-
April 24, 2012		* 200,000		-		-		-
June 28, 2012		2,400,000		600,000		-		-
July 6, 2012		20,580,000		5,144,990		-		-
		42,764,997	$	9,350,490	$	4,838,690	$	-

XML

Nature of Organization and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Nature of Organization and Significant Accounting Policies [Abstract]

Depreciation

Depreciation

The cost of property and equipment is depreciated over the estimated useful life of 3 to 7 years.  Depreciation is computed using the straight-line method when assets are placed in service. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals.

Basis of Accounting and Principles of Consolidation

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles and include the accounts of the Company and its wholly-owned subsidiary, Atlas Acquisition Corp. (formed on February 23, 2011 to facilitate the purchase of the intellectual property discussed in Note 8 - Intellectual Property Purchase Agreement).  All material intercompany balances and transactions have been eliminated.  These financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

Cash & Cash Equivalents

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be a cash equivalent.

Estimates

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.

Fair Value of Indefinite-Lived Intangible Assets

Fair Value of Indefinite-Lived Intangible Assets

The Company accounts for indefinite-lived intangible assets in accordance with ASC 350, Intangibles-Goodwill and Other.  In accordance with ASC 350, indefinite-lived intangible assets are subject to an impairment analysis at least annually, and more frequently upon the occurrence of certain events.  The impairment analysis is performed by comparing the fair value of the assets with the carrying value of the assets.  Fair value is estimated as the discounted value of future revenues arising from the use of such assets.  An impairment charge is recorded if the assets carrying value exceed the assets estimated fair value.

The Company's policy is to evaluate indefinite-lived intangible assets (e.g. the intellectual property) for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was $2,000,000.  Management performed their quarterly review of the intellectual property and determined no impairment existed and there was no change to the carrying value for the nine months ended September 30, 2013.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue when products are shipped and collection is reasonably assured.

Inventories

Inventories

Inventory consist of the following:
	September 30,		December 31,
	2013		2012
Raw materials	$	10,869	$	213,848
Work in process		-		-
Finished goods		-		4,469
Total Inventory	$	10,869	$	218,317

Inventories are stated at the lower of cost or market, with cost determined on a first in, first-out basis.

Advertising

Advertising

The Company charges the costs of advertising to expense as incurred. The Company incurred $924,368 and $260,427 of advertising and promotional costs for the nine months ended September 30, 2013 and 2012 respectively, and $1,518,930 since its inception.  Pursuant to its distribution agreement with Maximum Human Performance (“MHP”), entered into on May 16, 2012, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold (See Note 10 - Commitments, Contingencies and Other Comments - Distribution Agreement).

Fixed Assets

Fixed Assets

Fixed assets consist of the following:
	September 30, 2013			December 31, 2012
Furniture, fixtures and equipment	$	100,758		$	3,024
Computers and software		15,247			6,814
Leasehold improvements		233,954			-
Other		5,000			-
Total fixed assets		354,959			9,838
Less accumulated depreciation		(27,000	)		(1,449	)
Net book value of fixed assets	$	327,959		$	8,389

Repair and maintenance costs are expensed as incurred.  Depreciation expense was $25,553 and $771 for the nine months ended September 30, 2013 and 2012, respectively.

Concentrations of Risk, Significant Distributor and Customer and Significant Supplier

Concentrations of Risk, Significant Distributor and Customer and Significant Supplier

The Company maintains its bank accounts with a high credit quality financial institution and has never experienced any losses related to these bank accounts.  From December 31, 2010 through December 31, 2012, all non-interest-bearing transaction accounts were fully insured by the FDIC, regardless of the balance of the account and the ownership capacity of the funds, and interest bearing accounts were insured up to $250,000.  Beginning 2013, insurance coverage reverted back to $250,000 per depositor at each financial institution.  The Company had two noninterest-bearing checking accounts and one interest-bearing savings account which totalled $1,882,714 as of September 30, 2013.   At September 30, 2013, the Company's uninsured cash balances totalled $1,632,714.

Effective May 2012, MHP became the exclusive distributor and sole customer of the Company's MYO-X product and formula (see Note 10 - Commitments, Contingencies and Other Comments – Distribution Agreement).  MHP's exclusivity expired in September 2013.  While the distribution agreement otherwise remains in effect,  the parties are currently negotiating a new agreement.

The Company currently relies on one foreign company to produce the raw product for MYO-T12 (see Note 10 - Commitments, Contingencies and Other Comments – Supply Agreement).  The Company is considering other supply alternatives.

Equity Based Compensation

Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees.  ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model.  For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation.  Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables.  These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.  

Equity-based compensation expense for awards to employees and non-employees was $1,042,793 and $707,143 for the nine month periods ended September 30, 2013 and 2012, respectively. 

Comprehensive Loss

Comprehensive Loss

The Company had no items of other comprehensive income or expense for the nine month periods ended September 30, 2013 and 2012.  Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.

Research and Development

Research and Development

The Company incurred $398,199 and $18,279 of research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 and 2012 respectively, and $605,020 since its inception.

Segment Information

Segment Information

ASC 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information regarding operating segments in annual consolidated financial statements and requires selected information for those segments to be presented in financial reports issued to stockholders.  It also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The Company operates in a single segment, internally reports the results of operations for that segment and the information disclosed herein materially represents all of the financial information related to the single operating segment.

Fair Value Measurement

Fair Value Measurement

The Company adopted the provisions of ASC 820 Fair Value Measurements and Disclosures on January 1, 2009.  ASC 820 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.  Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy.  It does not require any new fair value measurements.  It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

Valuation techniques considered under ASC 820 techniques are based on observable and unobservable inputs.  The ASC classifies these inputs into the following hierarchy:

Level 1 inputs are observable inputs and use quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date and are deemed to be most reliable measure of fair value.

Level 2 inputs are observable inputs and reflect assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity.  Level 2 inputs includes 1) quoted prices for similar assets or liabilities in active markets, 2) quoted prices for identical or similar assets or liabilities in markets that are not active, 3) observable inputs such as interest rates and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, credits risks, default rates, and 4) market-corroborated inputs.

Level 3 inputs are unobservable inputs and reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

In October 2008, the FASB clarified the application of ASC 820 in determining the fair value of a financial asset when the market for that financial asset is not active.

The Company adopted the provisions of ASC 825, The Fair Value Option for Financial Assets and Liabilities, on January 1, 2009.  ASC 825 permits us to choose to measure certain financial assets and liabilities at fair value that are not currently required to be measured at fair value (the “Fair Value Option”).  Election of the Fair Value Option is made on an instrument-by-instrument basis and is irrevocable.  At the adoption date, unrealized gains and losses on financial assets and liabilities for which the Fair Value Option has been elected are reported as a cumulative adjustment to beginning retained earnings.

Our intangible assets are valued and tested for impairment using Level 3 inputs (see Note 8 - Intellectual Property Purchase Agreement).  In the process of the valuation of the intangible asset, we determined that the carrying cost exceeded the fair value at December 31, 2011 and we recorded an impairment charge and adjusted the balance of the asset to reflect the fair value.  There were no impairment charges for any subsequent periods.

Basic and Diluted Income (Loss) per Share

Basic and Diluted Income (Loss) per Share

In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding.  Diluted loss per common share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At September 30, 2013 and 2012, the Company’s stock equivalents were anti-dilutive and excluded in the diluted loss per share computation.  The aggregate number of potentially dilutive options and warrants outstanding at September 30, 2013 and 2012 were 11,091,000 and 1,650,000, respectively.

Income Taxes

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.

The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement.  This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements.  It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions.  The Company has no uncertain income tax positions.

Interest costs and penalties related to income taxes are classified as interest expense and selling, general and administrative costs, respectively, in the Company's financial statements.  For the nine months ended September 30, 2013 and 2012, the Company did not recognize any interest or penalty expense related to income taxes.  The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS Corp
Entity Central Index Key	0001402479
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		111,372,282

XML

Nature of Organization and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2013

Nature of Organization and Significant Accounting Policies [Abstract]

Summary of Inventory

	September 30,		December 31,
	2013		2012
Raw materials	$	10,869	$	213,848
Work in process		-		-
Finished goods		-		4,469
Total Inventory	$	10,869	$	218,317

Summary of Fixed assets

	September 30, 2013			December 31, 2012
Furniture, fixtures and equipment	$	100,758		$	3,024
Computers and software		15,247			6,814
Leasehold improvements		233,954			-
Other		5,000			-
Total fixed assets		354,959			9,838
Less accumulated depreciation		(27,000	)		(1,449	)
Net book value of fixed assets	$	327,959		$	8,389